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ABSTRACT 
 
N-linked glycans are post-translational modifications that link an oligosaccharide 
to an asparagine residue. The attached oligosaccharide then undergoes extensive 
modification in the Golgi apparatus prior to protein secretion. This type of modification 
helps with protein folding, resistance to protease activity, immunogenicity, and imparting 
biological activity. Antibodies, such as IgG1, offer an idealized system to study proteins 
containing an N-linked glycan. 
IgG1 is a homodimeric protein with a molecular weight of 150 kDa. It is 
composed of two heavy and two light chains, the heavy chain encompassing the Fab 
(fragment antigen binding) and Fc (fragment constant) and the light chain only being 
part of the Fab region. The two regions of IgG1, Fab and Fc, are linked by a hinge 
which contains several disulfide bonds creating a flexible linker allowing the Fab and Fc 
domains freedom to orient and bind their targets. The Fab region binds antigen and the 
Fc region binds immune receptors.  Under the proper conditions these receptors trigger 
a cellular response to an antigen.  
In this work we seek to understand how this cellular response is modulated by 
the N-linked glycans present on the Fc region. The Fc contains two N-linked glycans, 
which are attached in a region that is critical for immune receptor binding. It is thought 
that these glycans, through contacts across a beta sheet, restrict the motion of a loop 
region allowing for a high affinity interaction between the Fc region and immune 
receptors. Through NMR and X–ray crystallography studies we show that one specific 
loop becomes mobile when the glycan is truncated and that when a full glycan is 
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present the loops moves by more than 5Å. Fc with the truncated N-glycan binds 
receptor with 100-fold less affinity that Fc with a full glycan and thus this reorganization 
is incredibly important to understanding complex formation.  
Additionally, the immune receptors that interact with IgG molecules are 
themselves glycosylated. In this work we study the interaction of IgG1 Fc with CD16A, a 
receptor present on natural killer cells (NK cells). This receptor is responsible for the 
antibody dependent cell-mediated cytotoxicity, (ADCC), response from NK cells and 
which is a major tumor clearing mechanism in the body. Through several SPR and ITC 
experiments we show that one of the glycans present on CD16A can interact with the 
glycan on IgG1 Fc, which in turn can modulate the affinity of the complex. One such 
modification of the IgG1 Fc, the addition of a monosaccharide called fucose, disrupts 
the IgG1 Fc / CD16A complex. An analysis of extensive all-atom molecular dynamics 
simulations show that this modification causes a shift in conformation in the CD16A 
glycan interacting with IgG1 Fc potentially biasing it into an energetically unfavorable 
area leading to affinity loss. Both of these studies seek to better understand the role N-
glycans play in the interaction of Fc regions and their immune receptors to design better 
monoclonal antibody therapy treatments. 
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CHAPTER 1. INTRODUCTION TO THE N-LINKED GLYCOSYLATION OF IGG1 
 
N-Linked Glycosylation 
The first glycoprotein discovered was Ovalbumin because of an apparent mass 
discrepancy1. The exact nature of this linkage was probed by hydrolysis with several 
proteases and then chromatographed and compared to synthetic standards. These 
experiments demonstrated that asparagine was the amino acid involved and in the case 
of Ovalbumin the oligosaccharide was linked to the protein by an N-acetyl-D-
glucosamine2,3. Further analysis of other glycoproteins also demonstrated this linkage 
being present, and as more proteins were discovered each had the amino acid 
sequence proximal to the post-translational modification sequenced leading to the 
consensus sequence of Asn-X-Ser/Thr as a requirement of N-linked glycosylation4,5.  
Later experiments with small peptides would demonstrate that this consensus 
sequence was somewhat malleable in terms of the middle amino acid, but clearly 
demonstrating the proline was disallowed6. The mechanism of the consensus sequence 
was proposed to be that the hydroxyl group of the Ser/Thr would act as a hydrogen 
bond donor to the carboxyl group to neighboring asparagine thus stabilizing the terminal 
amino allowing it to be modified by oligosaccharyltransferase. This demonstrates then 
how a simple substitution such as a glutamine with asparagine would be damaging7. As 
researchers began uncovering more and more glycoproteins the consensus sequence 
Asn- any but proline – Ser/Thr was a definite requirement for glycosylation, it however 
did not guarantee a glycan would be present. Studies of oligosaccharide processing 
enzymes implicated the rough ER and Golgi apparatus as the site of addition and 
modification, respectively8–10. Therefore, cytosolic proteins with this sequon would not 
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get this modification, explaining part of this observation. Recent studies of the mouse 
glycome show that still only ~70% of proteins trafficked through the ER that contain a 
sequon get glycosylated11. This additional requirement that proteins must meet is one of 
structure around the sequon12,13. It was demonstrated that beta turns or loops 
represented the ideal geometry to optimize the hydrogen bond potential of the serine or 
threonine with the asparagine. Therefore, sequons that are buried or a part of an 
unfavorable structural element could never be accessed by the 
oligosaccharyltransferase. This underscores the nature of N-linked glycosylation as one 
that is not directly coded by the genome. 
Another observation made by researchers was the sheer number of possible 
glycans present on glycoproteins. It was found that N-glycoproteins from eukaryotes are 
synthesized from the same lipid linked precursor, (an oligo saccharide Glc3, Man9, and 
GlcNAc2), which is synthesized by cytosolic facing enzymes before being flipped into 
the ER for addition to the nascent polypeptide “en bloc” by 
oligosaccharyltransferase8,9,14,15. Studies have demonstrated that the processing 
enzymes present in eukaryotes are very specific and their regulation is tightly 
controlled14. Work by Roth et al, showed using a modified Protein A that the location of 
a galactosyltransferase was located only in the trans-golgi, similar experiments have 
gone to show this for a host of other enzymes such as GNT I-III, and mannosidases I-
II16–18. This system of glycan modification is clearly shown in Figure 1 as a type of 
assembly line. As observers noted, the beginning oligo saccharide may the same, but 
the end product could be any of a long list of glycans, which localization studies show is 
a trafficking network. It is still not entirely understood how each glycoprotein is 
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trafficked, but it is clear that the large amount of heterogeneity comes from not only the 
expression levels of the various glycosyltransferases, glycosylhydrolases, their 
corresponding substrates the nucleotide sugar donors19, but importantly which of these 
the nascent glycoprotein is exposed to20. This ability to change the composition of a 
glycan on a glycoprotein is seen as a method cells use to adapt to changing 
environmental factors much faster than a change in the genome propagating to a 
changed protein.  
 
Figure 1. N-glycan modification pathway in eukaryotes.  
 
Glycan modifications can impart drastic changes to proteins allowing for deeper 
specialization over traditional protein synthesis; hence the evolutionary advantage of 
creating such a complex network. In general glycans and proteins interact through 
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hydrophobic forces. These interactions especially with proteins that have hydrophobic 
faces can use the glycans to cover these zones to prevent aggregation by allowing the 
polar side of the glycan to face the solvent21. Covering proteins also can prevent 
unwanted hydrolysis by various proteases in solution, which is especially important for 
secreted proteins22. These hydrophobic interactions can also take on a second role: 
stabilization of tertiary structures not possible in the aglycosylated structure. This could 
happen in several ways, one being where the addition of the glycan allows an 
alternative folding pathway, or the direct stabilization of a glycan-protein contact that 
induces a conformation in the protein23–25. This last category is of major importance to 
this work in particular as it is the mechanism IgG uses to bind to cellular receptors26.  
Immunoglobulin G1 N-Glycosylation 
Immunoglobulin G is a model protein to study N-glycans due to its simple glycan 
profile and absolute requirement of this N-glycan allowing for interrogation of the 
glycan’s role.  IgG itself is an integral part of the humoral immune response27 and is 
secreted in large amounts from plasma B cells. The IgG family of proteins are based on 
an immunoglobulin fold, which is composed of two series of antiparallel beta sheets 
bound together by a disulfide linkage28. The IgG proteins contain many of these folds 
linked together to create a homodimeric protein that is roughly 150 kDa, in addition each 
monomer is then composed of a heavy chain and light chain. The light chain makes up 
half of the Fragment antigen binding domain (Fab), and has a variable and constant 
regions. Making up the other section of the Fab region is the heavy chain, which 
contains its own variable and constant regions. The variable regions are antigen specific 
and are different with each antibody as determined by clonal selection by the plasma 
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cells29. The constant domains are class specific, meaning all IgG1 antibodies while 
having variable regions that can vary all will contain the same constant region. This 
constant region consists of the other half of the Fab region as mentioned, as well a long 
flexible hinge region which bridges the Fab to the fragment constant region (Fc). This 
hinge region has a large amount of diversity between classes of IgG and is considered 
to be very flexible30 which is thought to account for the differing affinities to various 
receptors 31. The Fc region is responsible for the binding of various immune receptors 
and is largely the same between IgG subclasses. The sites of N-linked glycosylation are 
found on the Fc region and it has been demonstrated that these N-glycans are 
absolutely required for immune cell response 32,33 (there are many examples of this). It 
has also been shown that the Fab region does not require the Fc region to bind 
antigen34 and the likewise, the Fc can bind without Fab present35. 
 
Figure 2. Overall structure of IgG1 encompassing the Fab, hinge, and Fc regions. Blue 
regions denote the constant region of the heavy and light chain respectively. Red 
regions denote the variable region of the heavy and light chain respectively.  
 
The Fc region is composed of two domains: the Cγ2 and Cγ3, with the Cγ2 being 
the site of immune cell activation and N-glycosylation, and the Cγ3 is responsible for the 
homodimeric nature of IgG. As mentioned above, the N297 glycan present on the Cγ2 
Antigen 
binding 
Receptor 
binding 
Fab 
Hinge 
region 
Fc 
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domain is required for binding of the Fc to immune receptors. It is thought that the 
glycan remodels part of the C’E loop (which is the loop N297 is a part of) as large scale 
changes are not seen upon aglycosylation with NMR RDCs36. Attempts to study an 
aglycosylated structure with crystallography have been hampered by the inability to 
obtain high quality datasets37. Barb et al, showed that this N297 glycan makes several 
important contacts with the Fc polypeptide interface at positions D265, F241, and 
F24338. D265 forms a hydrogen bond with the first GlcNAc which in turn is thought to 
directly stabilize the C’E loop as it is closer in proximity than either the phenylalanine 
residues. It is this interaction which is thought to allow the truncated IgG1 Fc’s ability to 
bind receptors36,39. Additionally, the F241 and F243 contacts are largely hydrophobic, 
and stack well with the mannose and GlcNAc residues on the attached N-glycan. These 
contacts also stabilize the glycan chain and bias it towards to bi-antennary complex-
type glycan36. It should be noted that mutation of these residues negatively impacts 
binding of the IgG1 Fc to immune receptors, as it frees the glycan from the polypeptide 
surface destroying any stability imparted to the C’E loop. Given the extent of 
polypeptide structure devoted to stabilizing the N297 glycan, it still shows a large 
degree of motion in solution NMR experiments40. This motion is thought to allow the two 
branches to be remodeled with varying degrees of galactose and sialic acid. These 
additions directly impact the overall affinity the Fc has for the Fc gamma receptors 
(FcγRs). 
The additional of galactose and sialic acid to the terminals of the IgG1 Fc glycan 
and their effects on structure and affinity differences that result are curious as these 
sites of modification lie far away from either the C’E loop or FcγR binding interfaces. 
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Galactose addition has been implicated to serve as an affinity enhancer, whereas sialic 
acid’s role in terms of affinity modulation is less clear41. Structural studies of the effect of 
galactose addition have shown that the structure of the Fc is influenced, presumably by 
influence with a neighboring lysine residue to the galactose, leading to greater glycan 
stabilization42,43. Sialic acid addition however does not seem to significantly alter Fc 
glycan dynamics44. Other roles hypothesized for the sialic acid addition have centered 
on an anti-inflammatory role45, however studies of intravenous IgG therapies have 
shown that sialic acid is not required for activity46. Regardless, these modifications are 
routinely monitored as they have been correlated as biomarkers for several disease 
states in humans47–49. 
Another modification to the IgG N-glycan besides varying levels of galactose and 
sialic acid is that of an addition of an alpha linked L-fucose to the asparagine linked 
GlcNAc at the six position. Several studies have shown that the addition of fucose 
decreases the affinity of Fc to FcγRs, by 10 to 50 fold50–52. While fucosylation is 
incredibly common, serum IgG is ~95% fucosylated53, there are specific instances when 
fucose is absent leading to an improved in vivo response54. As a result many attempts 
at glycoengineered monoclonal antibodies (mAbs) have strived to completely eliminate 
this modification to improve efficacy55. This then would suggest that there is some 
mechanism at play to regulate fucosylation and allow the body to pick which of its IgGs 
are going to be more potent over a large background present in the serum (5-10 mg/mL 
IgG is present56). Currently, the mechanism of this determination is not known; however 
the mechanistic effect of fucose on the Fc:FcγR interaction has been probed by several 
groups.  
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The prevailing hypothesis put forward independently by Matsumiya et al57, and 
Ferrara et al58 suggests that the fucose interrupts contacts of the receptor sugar and 
with the IgG1 Fc Cγ2 domain. Matsumiya et al demonstrate this through two crystal 
structures of the FcγRIIIa complex with IgG1 Fc with and without fucose. They note that 
while overall the structures are the same there are slight differences in the local region 
surrounding the N297 glycan on the IgG1 Fc Cγ2 domain, primarily the C’E loop. 
Ferrara et al, also through crystallography, proposed a very similar mechanism, with 
several potential hydrogen bonds present in their structures between receptor and Fc 
sugars. Fucose again, interrupts these contacts, which they hypothesize leads to a 
weakening affinity of the complex. The interruptions are all localized around C’E loop 
region, which in addition to the N-linked asparagine, contains a tyrosine residue 
immediately preceding the asparagine at position 296. Studies concerning this tyrosine 
residue show that it has the potential to interact with the fucose residue via Van der 
Waals contacts. It is possible that this interaction is what is stabilizing the C’E loop away 
from its higher affinity conformation59. A study that exchanged tyrosine 296 with the 19 
other amino acids showed that aromatic residues do as well or better in this position, 
with tryptophan having the highest affinity60 further supporting an interaction hypothesis. 
This hypothesis of stability however is somewhat contradicted by a recent study that 
used replica-exchange MD to demonstrate that the fucose leads to a larger variety of 
conformations of the receptor sugar61. Despite these contradictions it is clear that the 
fucose has a significant effect, however this effect does not elicit a large global change 
making studying it difficult. The differences in affinity between the fucosylated and 
afucosylated structures amounts to the equivalent energy of approximately a hydrogen 
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bond. This may seem insignificant in the terms of the scale of this interaction, which 
spans the Cγ2 domain as well as sections of the adjacent Cγ262,63, however in terms of 
the in vivo context it is believed to make a large difference when the avidity of many 
binding events present on Natural Killer cells are combined  leading to an immune 
response.  
Natural Killer Cell Activation 
A relevant system to consider IgG affinity with FcγR is that of the Natural Killer 
cell (NK cell) which expresses only one receptor that interacts with IgG, FcγRIIIa, 
making study of the complex more straightforward over that of other systems which 
display a variety of FcγRs. NK cells originate in the secondary lymphoid tissue, and go 
through several stages of development, ending with populations that displays a bright or 
dim staining of CD5664. This CD56dim population is thought to be the largest effector of 
Antibody-dependent cell-mediated cytotoxicity or ADCC in humans64–66. This process 
consists of an aberrant cell, such as a virus–infected cell or tumor cell, being opsonized 
by IgG. This immune complex then comes in contact with the FcγRIIIa on the NK cell 
surface. As these receptors bind the opsonized cell, the receptors start to cluster 
together, this event causes the immunoreceptor tyrosine activation motifs (ITAM) 
cytosolic domains to crosslink and release a signal cascade that results in the release of 
granzyme and perforins67. These compounds then engage the apoptotic mechanisms of 
the target cell resulting in its destruction (Figure 3). 
ADCC is thought to be a major mechanism of tumor cell clearance, in which NK 
cells play a large role68. As we consider ADCC however there are a few points to note: 
the Fab and Fc regions of antibodies bind independently of each other, and serum 
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concentrations of IgG reach 5-10 mg/mL. This means that any NK cell with FcγRIIIa 
present will be coated by IgG molecules that may or may not have anything bound to 
their Fabs. In addition, the aberrant cell, will be coated as well setting the stage for the 
IgG coating the NK cell needing to be displaced before any kind of immune response 
can be reached. Any slight affinity advantage will see that antibody supplant a weaker 
one, leading to the eventual binding of FcγRIIIa to the highest affinity IgG. This binding 
then would bias other receptors in the area to see predominately other IgGs present on 
the aberrant cell, accelerating receptor clustering with the avidity of the IgGs being a 
major driver in cellular response. The glycan modifications mentioned above are exactly 
how this is accomplished. The IgG Fc can strengthen affinity by increasing the amounts 
of galactose and sialic acid, and just as importantly reduce affinity by adding fucose. 
These levers then serve as a mechanism in which the immune system can pick which 
antibodies will have a larger effect41, as their affinity would be the highest of the IgG 
pool. It is this concept that guides mAb engineering to strive for the highest affinity to 
increase the efficacy of the treatment41,69,70. 
 
Figure 3. Antibody Dependent Cell-mediated Cytotoxicity (ADCC) as a major 
mechanism of tumor clearance via NK cells.   
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CHAPTER 2. CARBOHYDRATE-POLYPEPTIDE CONTACTS IN THE ANTIBODY 
RECEPTOR CD16A IDENTIFIED THROUGH SOLUTION NMR SPECTROSCOPY 
 
A communication in Biochemistry doi: 10.1021/acs.biochem.7b00392 
Ganesh P. Subedi, Daniel J. Falconer, Adam W. Barb 
 
Abstract  
Asparagine-linked carbohydrates (N-glycans) are a common modification of 
eukaryotic proteins that confer multiple properties including the essential stabilization of 
monoclonal antibodies. Here we present a rapid and efficient strategy to identify N-
glycans that contact polypeptide residues and apply the method to profile the five N-
glycans attached to the human antibody receptor CD16A (Fc γ receptor IIIA). Human 
embryonic kidney 293S cells expressed CD16A with [13CU]-labeled N-glycans using 
standard protein expression techniques and medium supplemented with 3 g/L [13CU]-
glucose. Anomeric resonances on the protein-linked N-acetylglucosamine residue at the 
reducing end of the glycan are particularly well suited to studies of multiply-glycosylated 
N-glycoproteins because only one reducing end and nitrogen-linked residue is present 
in each N-glycan. Correlations between anomeric 1H1-13C1 nuclei on the reducing end 
residue generate crosspeaks in a conventional 2d heteronuclear single quantum 
coherence NMR experiment that appear in a region of the spectrum devoid of other 
carbohydrate peaks or background protein signals. Two N-glycan peaks corresponding 
to the N45 and N162 N-glycans were dispersed from the rapidly averaged peaks 
corresponding to the N38, N74 and N169 N-glycans. We used a combination of NMR 
18 
 
 
and 1 µs all-atom computational simulations to identify unexpected contacts between 
the N45 N-glycan and CD16A polypeptide residues.  
Introduction 
Asparagine-linked carbohydrates (N-glycans) are common eukaryotic protein 
modifications that contribute structural stabilization, epitopes for receptor interactions, 
longevity in the serum, markers for intracellular trafficking, protection from antibody 
recognition and proteases, as well as antigen presentation in the immune system 1-8. A 
high percentage of secreted and cell surface human proteins are likely N-glycosylated 
and many contain multiple modifications though not all N-glycans contribute to structural 
stabilization 9, 10. Glycoprotein stabilization through carbohydrate/polypeptide contacts is 
a critical role for N-glycans and the primary function of the essential and conserved 
immunoglobulin G N-glycan in therapeutic monoclonal antibodies and the human 
immune system 1, 2, 11. Currently, rapid structure-based methods to identify and 
characterize N-glycans that contribute to glycoprotein structure and function by 
interacting with polypeptide residues do not exist. Furthermore, approaches to 
characterize N-glycans lag behind other related protein spectral methods because 
common recombinant protein expression systems like Escherichia coli do not N-
glycosylate. Here we present a solution-based method to identify N-glycans that form 
intramolecular interactions with polypeptide residues that uses standard glycoprotein 
expression techniques. 
 N-glycans can be extensive features with dozens of sugar residues 12, 13, 
however, Kelly and coworkers demonstrated the predominant N-glycan contribution to 
the stabilization of CD2 came from the N-acetylglucosamine (GlcNAc) residue at the 
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reducing end and point of attachment to asparagine 14. Thus, we probed the 1-bond 
correlation between anomeric carbon (C1) and proton (H1) nuclei by solution NMR 
spectroscopy as a potential reporter of intramolecular interactions between N-glycan 
and polypeptide residues using the soluble extracellular domain of human CD16A (Fc γ 
receptor IIIa) that contains five N-glycosylation sites to identify which contribute to 
antibody binding. CD16A is a membrane protein with two N-terminal extracellular 
antibody-binding domains, a transmembrane spanning region and a short intracellular 
domain. CD16A is expressed mainly on natural killer cells and monocytes/macrophages 
and activates an immune response by binding antibody-coated particles. 
Results 
 CD16A expressed from HEK293S cells grown in commercially available, 
chemically-defined media formulations contained a high degree of glycosylation with 
nearly homogenous oligomannose N-glycans (complete details are available in the 
Supplemental Methods section) 15-17. Supplementing commercial HEK293 growth 
medium with 3 g/L [13CU]-glucose efficiently labeled CD16A carbohydrate residues but 
showed minimal, if any metabolic scrambling into amino acids in a 2d 1H-13C HSQC 
experiment which is not surprising because the medium contains high concentrations of 
amino acids (Figure 1). Correlations between anomeric protein and carbon nuclei 
provide clear signals for each sugar residue in the glycan, and are resolved from other 
protein and carbohydrate peaks with 13C resonance frequencies between 80-105 ppm. 
Unfortunately, this strategy provides as many as 35 signals for CD16A and it is 
challenging to identify signals coming from a single N-glycan. The N-acetylglucosamine 
residue at the N-glycan reducing end ((1)GlcNAc) represents the only residue of each 
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glycan that contains a linkage to a nitrogen atom; all other residues are linked through 
an oxygen atom. This difference isolates peaks from the (1)GlcNAc residues on CD16A 
in region of the spectrum from 80-85 ppm (13C) that lacks protein or other carbohydrate 
resonances (dashed box, Fig 1). Expansion of the spectrum to cover these correlations 
reveals four peaks (Fig 2); two are resolved and separated and two intense peaks 
partially overlap in the spectrum. The peak at the far left of the spectrum is considerably 
weaker and broader than the other three peaks. It was interesting to note that digesting 
CD16A with endoglycosidase F (Fig S1), which cleaves between glycan residues 1 and 
2, did not alter the spectrum to a significant extent, consistent with the report by Kelly 
and coworkers noted above that the (1)GlcNAc residue provided the predominant 
stabilizing contribution of the N-glycans 14. 
 
Figure 1. 1H-13C HSQC spectrum of [13C-glycan]-CD16A. The region corresponding to 
the peaks from the anomeric correlations of asparagine-linked N-acetylglucosamine 
residues are highlighted with a dashed box. CD16A contains exclusively oligomannose 
(Man5) N-glycans as shown by the cartoon in the lower right. (Performed by GPS) 
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Figure 2. A region from 1H-13C HSQC spectra of [13C-glycan]-CD16A show anomeric 
correlations originating from the asparagine-linked N-acetylglucosamine residue. 
Glycosidase or trypsin digestions of wild type CD16A with 5 N-glycans are shown in the 
left column. CD16A mutated to prevent one or more N-glycosylation modifications 
revealed peak assignments (right column). (Performed by GPS) 
 
 Intramolecular interactions between glycan and polypeptide residues were 
destroyed by trypsin digest to generate unstructured peptide and glycopeptide 
fragments. A spectrum of proteolyzed CD16A showed the dispersed spectrum 
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collapsed into two intense and partially overlapped peaks that indicate the two peaks 
identified in the intact CD16A spectra shifted from the intense overlapped peaks due to 
glycan/polypeptide interactions and not amino acid sequence differences near the N-X-
S/T sequon (Fig 2). This result also provides a clear expectation for resonance 
frequencies of (1)GlcNAc 1H1-13C1 correlations from N-glycans in minimally or 
unstructured regions. 
 Mutating asparagine residues located in the three residue N-X-S/T N-glycan 
consensus sequons to glutamine prevented N-glycan attachment during protein 
expression and provided N-glycan specific assignments for CD16A. Proteins with a 
single N-glycan site expressed poorly and proved unstable. Combinations of single or 
triple mutations identified the asparagine residue position for each N-glycan peak. The 
two intense and partially overlapped peaks contained resonances from N-glycans at 
N38, N74 and N169 (Fig 2). These N-glycans do not appear to interact with the CD16A 
polypeptide based on peak intensity and a position that is coincident with N-glycans 
from proteolyzed CD16A that suggest rapid motional averaging of multiple 
conformations. The peak located just to the upper left of these resonances, shifted by 
0.1 ppm 1H/-1.0 ppm 13C relative to the N38/N74/N169 peaks, belongs to the N162 N-
glycan.  The peak in the lower left, shifted by 0.5 ppm 1H/0.5 ppm 13C, belongs to the N-
glycan attached to N45.  
We investigated the relative motion of the five CD16A N-glycans with molecular 
dynamics simulations to provide more insight into possible motions experienced by 
each N-glycan. An 850 ns simulation of the extracellular domain of CD16A revealed that 
the N45 N-glycan experienced less motion than the N-glycans at N38, N74, N162 or 
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N169 at each residue position based on analysis of a root mean square fluctuation 
value (RMSF; Fig S2). The N38, N74 and N169 N-glycans neither stabilize CD16A (Fig 
2) nor contribute much to antibody binding 18-20 and therefore investigation of CD16A 
with only the N45 and N162 N-glycans is justified. A 1 µs simulation of CD16A lacking 
the three most mobile N-glycans (N38/N74/N169) showed a similar difference in N45 
and N162 mobility as in simulations of the wild-type CD16A (Fig 3). The N45 N-glycan 
residues showed low RMSF values that were ~1/3 the values for corresponding N162 
N-glycan residues and RMSF clearly separates N162 and N45 N-glycans at the 
(1)GlcNAc residue, corresponding to the NMR measurements (Fig 2).  
 
Figure 3. All-atom molecular dynamics simulation (1 µs) of N-glycosylated CD16A 
reveals large differences in N-glycan mobility. The N162 N-glycan samples a large 
space (blue cloud, left figure) unlike the N45 N-glycan with restricted mobility (grey 
cloud). RMSF values for N-glycan residues in these simulations likewise reflect the 
relative mobility of each N-glycan. (Performed by DJF) 
 A detailed analysis of intramolecular interactions involving the N45 N-glycan 
revealed a mode of stabilization that is centered around interactions with the (1)GlcNAc 
residue. The (1)GlcNAc residue on the N45 N-glycan forms two important interactions 
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with E68 and D64 that are maintained for the duration of the 1 µs simulations and are 
poised to restrain residues 53 to 66. The importance of these contacts was verified in a 
1 µs all-atom simulation of aglycosylated CD16A. Residues 40-55 and 60-70 showed 
much greater disorder in a simulation of aglycosylated CD16A than the corresponding 
regions of glycosylated CD16A (Fig S3). Furthermore, the N45-stabilized loop 
corresponding to residues 60-70 occupied a stabilized structure that completely unfolds 
in the simulation of aglycosylated CD16A. Shields and coworkers identified the 
importance of these residues and connected secondary structural elements that include 
W90 and W113 that form a cage around P329 of IgG1 Fc 21. W90 and W113 reside 
between N45 and N162 and are poised to be affected by local stabilization mediated by 
N45. The role of stabilizing N45 N-glycan contacts is further supported by our 
observations that N45 enhances recombinant CD16A expression. A CD16A mutant with 
only the two N45 and N162 N-glycans expressed at a high level, but the CD16A form 
with one N-glycan at N162 expressed with very low yield (data not shown). 
Position-specific N-glycan assignments and all-atom molecular dynamics 
simulations provided a new window to CD16A structure and function. It is not surprising 
that the N162 peak was not resolved in a spectrum of the CD16A N45Q mutant. The 
stabilization provided by the N45 N-glycan appears to impact the conformation near 
N162 because the N45 N-glycan appears to form the strongest interactions with the 
CD16A polypeptide based on the degree of peak shift when compared to the spectrum 
of proteolyzed CD16A and the simulations of glycosylated and aglycosylated CD16A. It 
was surprising, however, that the N45 N-glycan showed the greatest interaction of the 
five N-glycans. Perhaps the unique location of N45 at the end of a loop formed by 
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residue 42-50 provides more potential N-glycan/polypeptide interactions. This location is 
comparable to the N297 N-glycan on IgG1 Fc that forms a distinct intramolecular 
interface with polypeptide residues and unlike the four other CD16A N-glycans 1. 
Previous work indicated that primarily the N45 and N162 N-glycans contributed to 
antibody binding 18, 19. N-glycans at N38, N74 and N169 likely do not contribute and 
were removed for crystallization of the CD16A/IgG1 Fc complex 19, 20. The N162 N-
glycan is involved in IgG1 Fc binding and the N45 N-glycan is located on a domain that 
does not contact IgG1 Fc directly. 
 The strategy described here provides an accessible, rapid and efficient method 
to identify N-glycans that contact polypeptide residues and are poised to contribute to 
glycoprotein stability and function. This technique uses standard protein expression and 
isotope labeling methods that are accessible to most laboratories. N-glycan resonances 
from the anomeric carbon at the reducing end of the N-glycan provide a limited number 
of well resolved signals that are observable using standard 2d NMR experiments 
available on standard spectrometers with two channel capability. These methods are 
likely applicable to most glycoproteins and isolated domains with one or more N-
glycans, as demonstrated here.  
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CHAPTER 3. MOUSE IGG2C FC LOOP RESIDUES PROMOTE GREATER 
RECEPTOR-BINDING AFFINITY THAN MOUSE IGG2B OR HUMAN IGG1 
 
A paper in PLoS One doi: 10.1371/journal.pone.0192123 
Daniel J. Falconer, and Adam W. Barb 
All experiments were performed by DJF 
Abstract 
The structures of non-human antibodies are largely unstudied despite the 
potential for the identification of alternative structural motifs and physical properties that 
will benefit a basic understanding of protein and immune system evolution as well as 
highlight unexplored motifs to improve therapeutic monoclonal antibody. Here we probe 
the structure and receptor-binding properties of the mouse IgG2c crystallizable fragment 
(Fc) to compare to mouse IgG2b and human IgG1 Fcs. Models of mIgG2c Fc 
determined by x-ray crystallography with a complex-type biantennary (to 2.05 Å) or a 
truncated (1)GlcNAc asparagine-linked (N)-glycan attached (to 2.04 Å) show differences 
in key regions related to mouse Fc γ receptor IV (mFcγRIV) binding. Mouse IgG2c 
forms different non-bonded interactions between the BC, DE and FG loops than the 
highly-conserved mIgG2b and binds to FcγRIV with 4.7-fold greater affinity in the 
complex-type glycoform. Secondary structural elements surrounding the Asn297 site of 
glycosylation form longer beta strands in the truncated mIgG2c Fc glycoform when 
compared to mIgG2c with the complex-type N-glycan. Solution NMR spectroscopy of 
the N-linked (1)GlcNAc residues show differences between mIgG2b, 2c and hIgG1 Fc 
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that correlate to receptor binding affinity. Mutations targeting differences in mIgG2 DE 
and FG loops decreased affinity of mIgG2c for FcγRIV and increased affinity of mIgG2b. 
Changes in NMR spectra of the mutant Fc proteins mirrored these changes in affinity. 
Our studies identified structural and functional differences in highly conserved 
molecules that were not predicted from primary sequence comparison. 
Introduction 
 Antibodies protect against invading pathogens and diseased tissue through a 
host of different mechanisms, including neutralization, antibody-dependent cell 
mediated cytotoxicity (ADCC), complement-mediated cytotoxicity, phagocytosis, and 
trogocytosis. ADCC, as the name implies, is triggered when an IgG-coated particle 
engages certain Fc γ receptor (FcγR)-expressing leukocytes. Phagocytosis and 
trogocytosis can likewise be triggered through FcγR-mediated mechanisms. FcγRs bind 
IgG through the invariant homodimeric crystallizable fragment (Fc) formed by the C-
terminal halves of the gamma heavy chain (Fig 1). Receptor binding interactions are 
sensitive to the subclass of IgG, with human IgG1 and 3 eliciting a response at lower 
concentrations than IgG2 and 4 [1]. 
FcγRIIIa/CD16A is the primary receptor that triggers ADCC in humans. CD16A 
preferentially binds IgG1 and 3 over IgG2 and 4 [3], and is expressed as the only FcγR 
on natural killer cells, but is also expressed on some populations of 
monocytes/macrophages [4]. A related molecule, CD16B is expressed on neutrophils 
and potentiates similar responses. The murine adaptive immune is similar with IgG2 
antibodies and mFcγRIV comparable to hIgG1 and hCD16A, respectively, though no 
hCD16B homolog is known in mouse [5]. Mouse FcγRIV is expressed on neutrophils 
30 
 
 
and monocytes/macrophages and a recent study indicates mFcγRIV shares multiple 
unique functional features associated with hCD16A, reinforcing the identity of these two 
proteins as homologues [6]. Though numerous studies described the structure and 
function of human IgG1 and the IgG1 Fc:CD16A interaction (including but not limited to 
[7-20]), much less is known about the mIgG2 structure and the mIgG2:FcγRIV complex 
despite the central role for mice strains in developing and testing monoclonal antibody 
therapies. Different antibodies provide the potential to understand disparate functional 
solutions selected by evolution in antibodies that are highly conserved at the primary 
sequence level, despite the potential for subtle differences at the antibody/receptor 
interface between human and mouse, and are expected to inform future antibody 
development efforts.
 
Figure 1. Mouse IgG2c Fc is comparable to other IgGs but shows differences in crucial 
features. A. A cartoon model of mouse IgG2c Fc solved by x-ray crystallography. 
Domain and secondary structure element labels (B.) are noted. C. An overlay of two 
mouse IgG2c Fc models with different N-glycan composition. D. A cartoon schematic 
showing the glycoforms studied here, individual carbohydrate residues are indicated by 
colored shapes according to the SNFG system [2]. The colors of individual Fcs will be 
used as indicated throughout the text to denote sequence and glycan variants. E. 
Sequence and secondary structure arrangement of the Fc Cγ2 domains. Hinge and Cγ3 
residues are not shown. 
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 Mice strains express three IgG2 subclasses: IgG2a, 2b and 2c that share 74-
80% primary sequence identity in the hinge and Fc regions with greatest similarity in the 
receptor binding Cγ2 domains (Fig 1E). Mouse IgG2a is highly polymorphic [21] with 
less variability described for the heavy chains of mIgG2b and mIgG2c. While mouse 
IgG2b is encoded by a distinct gene and likely present in all mice, the Igh-1a and Igh-1b 
genes encoding the mIgG2a and 2c heavy chains, respectively, appeared to be allelic 
with dramatically different allele frequencies found in different strains [21]. Four 
structures of mIgG2a and 2b are available in the protein database, and no structures of 
mIgG2c have been described [22-25]. 
 IgGs in all systems thus described require co-translational modification for 
effector function. A three amino acid sequon of Asn-(any non Pro residue)-Ser/Thr is 
modified by the oligosaccharyltransferase complex that adds a 14-residue carbohydrate 
to the sidechain nitrogen atom of Asn297 (an N-glycan). This carbohydrate is trimmed 
and extended by glycosylhydrolase and glycosyltransferase enzymes in the ER and the 
Golgi during protein secretion, resulting in the expression of antibodies that contain 
primarily a complex-type biantennary N-glycan that varies primarily in the amount of 
galactose at the two non-reducing termini [2]. In addition to the requirement of the N-
glycan for FcγR interactions, the composition of the N-glycan also impacts receptor 
binding affinity, primarily CD16A [14, 19, 26]. The correlation between antibody N-
glycan composition and receptor binding affinity can be explained by the work of our 
group that showed the N-glycan specifically stabilizes the hIgG1 Fc C'E loop and 
increasing the N-glycan length adds further stabilizing intramolecular contacts [16-18, 
20, 27]. Thus, intramolecular contacts between N-glycan and polypeptide residues are 
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critical features of antibody structure and receptor binding function. Probing differences 
in N-glycan structure and motion promises to provide insight into antibody 
structure/function relationships.  
 
Figure 2. 2d HSQC spectra of the Fc N-glycan (1)GlcNAc 1H1-13C1 reveals orthologous 
Fcs provide different N-glycan environments. The spectra of human IgG1 Fc were 
previously reported [20]. 
Our group recently reported a strategy to quickly identify interactions between N-
glycans, in particular the asparagine-linked (1)GlcNAc residue, and polypeptide 
residues with 2d 13C-HSQC spectra of HEK293-expressed and 13C[glycan]-labeled 
glycoproteins [28]. We identified two CD16A N-glycans that contribute to antibody 
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binding activity; the three remaining N-glycans showed little interaction. We also 
identified hIgG1 Fc residues that contribute to structural stabilization of proximal N-
glycan residues and promote CD16A binding [20]. The 1H1-13C1 correlation on the 
hIgG1 Fc (1)GlcNAc residue showed two resolved peaks that were consistent with 
CD16A binding activity (Fig 2). Mutations that disrupted structure or glycosylation of the 
C'E loop caused the two peaks to collapse into one peak and likewise disrupted CD16A 
binding. N-glycan truncation to a single (1)GlcNAc residue preserved both the spectral 
features and receptor binding properties of hIgG1 Fc and simplified the NMR spectra. 
With this expression and NMR technique we investigated mouse antibody fragments 
and characterized differences in structure and function between mouse IgG2b and 2c 
Fc. 
Materials and Methods 
All materials purchased from Sigma-Aldrich unless noted.  
Protein expression and purification  
 Mouse Fc expression constructs were prepared by amplifying open reading 
frames corresponding to the Fc and hinge regions from heavy chain expression 
constructs for mIgG2b and 2c provided by Prof. Falk Nimmerjahn (University of 
Erlangen-Nuremberg). These fragments were cloned into the pGen2 vector NotI and 
BamHI sites [29] that encoded residues 224-447 for mIgG2b Fc, and mIgG2c Fc 
residues 224-447 or mIgG2c Fc residues 209-447(only used for crystallizing mIgG2c Fc 
with the truncated (1)GlcNAc N-glycan). Mouse Fc mutations were prepared with the 
fusion PCR protocol [30] and verified by DNA sequencing (ISU DNA sequencing 
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facility). Mouse antibody fragments were expressed using HEK293F (Life Technologies) 
or HEK293S cells [31] grown in a mixture of 90% Freestyle293 (Life Technologies) and 
10% ExCell media as previous described [29]. Fc expressions were purified on a 5 mL 
protein A-sepharose column eluted with 5x 5 mL 100 mM glycine, pH 3.0. Fractions 
were immediately neutralized with 2.5mL 1 M Tris, pH 8.0. Protein was exchanged into 
20 mM MOPS, 100 mM sodium chloride, pH 7.2, using an Amicon 10 kDa cut off 
centrifugal filter and stored at 4°C. 
DNA encoding mouse FcγRIV (residues Q19–D191) was cloned into the pGen2 
vector using the EcoRI and HindIII sites to express an 8xHis and N-term GFP-tagged 
protein. Mouse FcγRIV was expressed in HEK293F cells grown in a mixture of 90% 
Freestyle293 (Life Technologies) and 10% ExCell media as described above and 
purified using a Ni-NTA agarose column (Qiagen). Purified receptor was exchanged into 
20 mM MOPS 100 mM sodium chloride, pH 7.2, using an Amicon 10 kDa cut off 
centrifugal filter. FcγRIV was stored at -80°C after adding glycerol to a final (v/v) ratio of 
25%.   
N-glycan remodeling  
N-glycans from HEK293S(lec-/-)-expressed Fc were truncated using either 
endoglycosidase F1 or endoglycosidase S depending on the absence or presence of 
fucose on the Fc, respectively. Endoglycosidase was added in a 1:50 molar ratio to Fc 
in 20 mM MOPS, 100 mM sodium chloride, pH 7.2 for 18 h at RT. Digestion was 
assessed using SDS-PAGE(Supplementary Fig 3). Remodeled Fc (not 8xHis-tagged) 
was purified from endoglycosidase F1 (8xHis-tagged) by flowing over Ni-NTA agarose 
resin.  
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Binding measurements  
Mouse IgG2b Fc and IgG2c Fc were immobilized on a CM5 sensor chip using 
amine coupling on a Biacore T100 (GE Healthcare). Lane 1 was used for a control with 
no protein immobilized. Carboxymethyl dextran was activated by flowing over a 1:1 
mixture of 0.4 M 1-ethyl-3(3-dimethylaminopropyl)carbodiimide and 0.1M N-hydroxy-
succinimide for 7 min at 5 µL/min. Mouse IgG samples were diluted to a concentration 
of 1 µg/mL in 10 mM sodium acetate, pH 5.0, and flowed over the CM5 chip for 10 min 
at 5 µL/min. Unreacted sites were blocked with 1 M ethanolamine, pH 8.5, for 7 min. 
Typical immobilization response units varied from 400-1000. The CM5 chip used a 
coupling buffer containing 20 mM MOPS, 100 mM sodium chloride, and 0.05% P20 
surfactant (GE Healthcare). The binding analysis buffer was identical but contained 1 
µM bovine serum albumin. All experiments were carried out at 25 °C. The CM5 chip 
was regenerated between runs with 100 mM glycine, pH 3.0, washes for 30 s to remove 
any bound receptor. Dissociation constants and rates were determined by averaging the 
values from at least two independent experiments. The error for this mean was 
determined by propagating the errors associated with the least-squares fit of each 
individual value. Differences in values were assessed by comparing the propagated 
error associated with each mean value. 
Crystallizing mouse IgG2c Fc  
Proteins were applied to a Superdex200 size exclusion column (GE Healthcare) 
pre-equilibrated with 20 mM MOPS, 100 mM sodium chloride, pH 7.2. Fractions 
containing Fc were identified using SDS-PAGE, pooled, and concentrated using an 
Amicon 10kDa cutoff centrifugal filter to 8-10 mg/mL. Initial screens for crystals were 
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carried out at 18 °C using the hanging drop vapor diffusion method. The mIgG2c Fc with 
a single (1)GlcNAc residue crystallized as large rod crystals when using the longer 
construct (residues 209-447) in 50 mM TRIS, pH 8.0, with 10% PEG 6K. Mouse IgG2c 
Fc with the complex-type glycan crystallized using the shorter construct (residues 224-
447) as large rod crystals in 50 mM HEPES, 5% PEG 3.35K, pH 7.0. 
X-ray data collection and processing  
Crystals were cryoprotected utilizing a quick soak in 20% glycerol (mIgG2c Fc 
with a truncated N-glycan) or 20% ethylene glycol (mIgG2c Fc with a complex-type N-
glycan). Diffraction data was collected at the Advanced Photon Source at Argonne 
National Laboratory on beamline 23-IDD using a PILATUS detector. Data was indexed, 
merged and scaled using HKL-2000. Iterative molecular replacement was performed 
using Phenix Phaser-MR and the mIgG2b protein model (PDB ID: 2rgs; [24]). Final 
refinement was performed using Phenix with automatically-generated non-
crystallographic symmetry restraints and translation-libration-screw restraints. 
NMR  
NMR spectra were obtained using a 700-MHz Bruker Avance II spectrometer 
equipped with a 5 mm cryogenically cooled probe and operated with TopSpin 3.2. 
Samples were exchanged into a buffer containing 20 mM potassium phosphate, 100 
mM sodium chloride, 0.5 mM DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid), pH 7.0, 
using an Amicon 10kDa cutoff centrifugal filter. All HSQC spectra were collected at 
50°C. Spectra were processed using NMRPipe and visualized using NMRViewJ (One 
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Moon Scientific). Proton and carbon frequencies were referenced to the internal DSS 
standard using the methyl proton resonance (0.07 ppm).  
Accession numbers  
Coordinates and structure factors have been deposited in the Protein Data Bank with 
accession numbers 6BHY (truncated) and 6BHQ (complex-type). 
Results 
Behavior of mouse IgG2 Fc differs from human IgG1 Fc 
Spectra of 13C[glycan]-labeled mIgG2b Fc and mIgG2c Fc, following 
endoglycosidase truncation, showed a single peak for the (1)GlcNAc anomeric 1H1-13C1 
correlation indicating differences in the chemical environment surrounding N297 (Fig 2). 
The peak from mIgG2c Fc showed a similar resonance frequency to the intense peak 
observed with hIgG1 Fc at ~4.99 ppm (1H). This intense peak was absent in a spectrum 
of hIgG1 Fc D265A that also showed no binding to CD16A [20]. The anomeric 1H peak 
from mIgG2b Fc appeared 0.07 ppm from the IgG2c Fc peak position and was 
comparable to a previously observation [32]. These spectra indicate mouse IgG2c and 
2b share a similar single anomeric peak feature and the potential for less local structural 
heterogeneity than human IgG1 Fc which has a well characterized dynamic C'E loop 
and C' strand [18, 20]. Furthermore, the resonance frequency of the mIgG2c peak is 
shifted to a lower 1H ppm value than mIgG2b. Based on hIgG1 Fc, the lower 1H ppm 
value for mIgG2c Fc is consistent with greater conformational restriction and the 
potential for tighter FcγRIV binding compared to mIgG2b Fc.  
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Mouse IgG2b and 2c bind FcγRIV with high affinity 
Mouse IgG2c Fc bound mFcγRIV with 1.5-fold greater affinity than mIgG2b Fc 
when both contained core-fucosylated complex-type N-glycans (Table 1; Fig S1). These 
mouse antibody fragments bound mFcγRIV with 30-40 fold greater affinity (12-18 nM, 
respectively) than hIgG1 Fc bound FcγRIIIa/CD16A (550 nM [20]). 
Table 1. Binding of mIgG2c Fc and mIgG2b Fc to mFcγRIV measured with surface 
plasmon resonance.  
  (1)GlcNAc N-glycan 
Kd ± err (nM) 
Complex-type N-glycan 
Kd ± err (nM) 
2b-wt 2800 ±110 18.0 ±0.3 
2b-I300L 1800 ±80 15.0 ±0.2 
2b-I300L/K326R/D327A 1300 ±970 8.0 ±0.1 
2c-wt 600 ±30 12.0 ±0.2 
2c-L300I 1000 ±50 9.0 ±0.1 
2c-L300I/R326K/A327D 1100 ±70 9.0 ±0.1 
 
Truncating the Fc N-glycan to display a single (1)GlcNAc residue reduced the 
binding of mIgG2c Fc by 50-fold, however, mIgG2c Fc displayed 4.7-fold greater 
binding than the similarly truncated mIgG2b Fc which was reduced by 155-fold following 
glycan truncation (Fig S2). This result is comparable to truncating the hIgG1 Fc N-
glycan which reduced binding by 11-fold [20]. Thus, an extended complex-type 
biantennary N-glycan enhanced binding for both human IgG1 and mouse IgG2b and 2c 
Fcs. 
Structure of mouse IgG2c Fc in two glycoforms  
We pursued the structure of these antibody fragments to define how differences 
in the amino acid primary sequence affect structure. Attempts to crystallize mIgG2c in 
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both the full length and truncated N-glycoforms provided diffracting crystals (Table 2). 
Mouse IgG2b Fc truncated to the (1)GlcNAc residue did not form crystals in our 
screens; a high-resolution model of mIgG2b Fc with a full length N-glycan was 
previously reported [24]. Models of both mIgG2c Fcs in a truncated (pdb id 6BHY) or 
full-length (pdb id 6BHQ) N-glycoform proved similar to mIgG2b and mIgG2a Fcs with a 
homodimeric assembly and comparable secondary and tertiary structure elements (Fig 
1A) [23, 24, 33]. Maps revealed clear electron density for all portions of the core Cγ2 
and Cγ3 domains with one exception: the Cγ2 domain from chain B of mIgG2c Fc with a 
full-length N-glycan crystallized in an asymmetric unit without contacts stabilizing the 
chain B Cγ2 domain and some residues of the BC, DE and FG loops were unresolved 
despite high resolution diffraction (2.05 Å). 
Two differences between mIgG2c Fc and mIgG2b Fc emerged upon comparing 
both models solved with a full-length N-glycan: a difference in quaternary structure and 
a difference in the DE loop. Mouse IgG2c showed a closer approach of the Cγ2 
domains and a more open Cγ2/Cγ3 angle (Table S2). Though the Cγ2 domains 
accessed different orientations, the overall structural similarity was high with a low rmsd 
for backbone atoms (0.4 Å), though some differences were evident. The DE loop of 
mIgG2c Fc N-glycan was shifted 2.0 Å relative to the same loop for mIgG2b Fc 
(measured from Y296 in an overlay of the Cγ2 domains; Fig 3). The N-glycans of these 
Fcs occupied nearly identical interfaces with polypeptide sidechains, thus restricting the 
differences between the position of N297 Cα residues to 0.8 Å in an overlay of the Cγ2 
domains. This DE loop displacement was due to the presence of a Leu residue at 
position 300 in mIgG2c Fc (mIgG2b I300) that forms van der Waals interactions with 
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Pro271 and shifts the Cα of residue 300 by 0.8 Å and R293 by 1.3 Å further away from 
the E strand relative to mIgG2b (Fig 3C). It is also interesting to note van der Waals 
interactions between the Y296 sidechain and the (0)Fuc residue in mIgG2c Fc were not 
observed for mIgG2b. 
A model of the mIgG2c Fc truncated to a (1)GlcNAc N-glycan revealed 
substantial differences in the Cγ2 conformation and the DE loop (Fig 4). The Cγ2 
domains of the mIgG2c Fc with the complex-type N-glycan and the truncated N-glycans 
compared with an rmsd of 0.5 Å. Beta character of the E strand extended by two 
residues which pulled the (1)GlcNAc residue of the truncated mIgG2c Fc upwards 
relative to mIgG2c with a full-length N-glycan, displacing the DE loop by 5.0 Å and 
shifting the BC loop by 1.5 Å for residues D269-P271 (Fig 4A). Crystal contacts were 
formed by DE-loop residues that would prevent the interconversion between the two 
distinct DE loop conformations observed in the crystals, however, based on the 
appearance of only one conformation from each glycoform despite screening crystals 
from multiple crystal conditions we believe the conformations presented here represent 
the predominant DE loop conformations sampled by each glycoform (Supplemental Fig 
4). Glycan truncation likewise impacted packing of the D strand against the E strand to 
form a beta sheet. This is evident from the carbonyl of D295 that is in hydrogen bond 
distance (3.0 Å) of the S298 amide. This distance increases to 3.8 Å and shifts the 
geometry away from a favorable hydrogen bond interaction in the structure containing 
the complex-type N-glycan. The truncated mIgG2c Fc glycoform also formed hydrogen 
bonds between E268, R293, and D295 further stabilizing the DE loop by coupling it to 
the BC loop. 
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Table 2. Summary of crystallographic data. 
 mIgG2c Fc N-glycoform 
 
(1)GlcNAc Complex-type 
PDB id 6BHY 6BHQ 
Wavelength (Å)  1.000 1.000 
Resolution range (Å) 44.61 - 2.04 (2.113 - 
2.04)* 
46.08 - 2.05 (2.123 - 2.05) 
Space group   C 1 2 1 P 21 21 21 
Unit cell (a b c ; Å) 103.233 89.215 69.851 67.735 73.399 118.408 
              ( ; °) 90.0 132.2 90.0 90.0 90.0 90.0 
Total reflections   110252 (9915) 179382 (14723) 
Unique reflections   29905 (2977) 37350 (3533) 
Multiplicity    3.7 (3.3) 4.8 (4.2) 
Completeness (%)   100 (100) 99 (95) 
Mean I/σ(I)   9.55 (1.75) 16.9 (1.9) 
Wilson B-factor (Å2)  33.22 40.55 
R-merge    0.093 (0.553) 0.047 (0.489) 
R-meas    0.109 (0.655) 0.052 (0.553) 
CC1/2    0.995 (0.756) 0.999 (0.810) 
Reflections used for R-free 6.3 % 9.9 % 
R-work    0.2106 (0.2798) 0.2369 (0.3303) 
R-free    0.2538 (0.3213) 0.2582 (0.3244) 
Number of non-hydrogen 
atoms  
3479 3551 
    macromolecules    3282 3160 
    ligands    34 198 
    water    163 193 
    protein residues   416 415 
RMS bonds (Å)    0.019 0.020 
RMS angles (°)    1.87 2.09 
Ramachandran favored (%)  98.0 98.0 
Ramachandran allowed (%)  2.2 1.8 
Ramachandran outliers (%)  0 0.0 
MolProbity Clash score    1.52 8.68 
B-factors (Å2)  
  
    average 38.4 55.01 
    macromolecules    38.16 53.94 
    ligands    58.45 78.14 
    solvent    39.10 48.8    
* values in parentheses refer to the highest resolution shell 
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Figure 3. Mouse IgG2c Fc and 2b Fc show a high degree of similarity with a complex-
type N-glycan, however, differences in loop residues impact conformation. A. Ribbon 
diagram of the mIgG2c Fc model shows clear Van der Waals contacts between Y296 
and (0)Fuc. B. The ribbon diagram for mIgG2b Fc shows a different organization of the 
DE loop. C. A comparison of the 2b Fc and 2c Fc models shows the effect of residue 
300 in DE loop conformation and D. sequence differences in the FG loop. 
This substantial reorganization was accompanied by a separation of the N-glycan 
from the stabilizing intramolecular interactions. The (1)GlcNAc residue and N297 
sidechain rotated 180° relative the position found in mIgG2c with the full-length N-
glycan. The low B-values (46 Å2) and resolution of this region are surprising (Fig 4D); 
the same (1)GlcNAc residue of hIgG1 Fc with the same truncation does not reorient, is 
less resolved and is characterized by higher B values (105 Å2) [34]. This comparison in 
conjunction with the NMR data above indicates that mIgG2c Fc contains a sequence 
motif that provides more interactions to stabilize this critical region than are present in 
hIgG1 Fc, however, the rearrangements upon truncation, including the extension of the 
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E strand, likely do not promote receptor binding as mIgG2c is more sensitive to glycan 
truncation than human IgG1 Fc (50-fold and 11-fold reduction, respectively; Table 1). 
 
Figure 4. Truncating the mIgG2c Fc N-glycan alters the DE loop conformation. A-B) 
Comparison of mIgG2c Fc models with a complex-type N-glycan (orange ribbon) with a 
truncated (1)GlcNAc N-glycan (green ribbon). C-D) Electron density of the DE loops 
show significant displacements in the loop conformation (contoured to 1.5 σ). E-F) 
Electron density of the N-glycans show the usual contacts in the case of full length 
glycan, and a 180° rotation of the (1)GlcNAc residue in the truncated glycoform 
(contoured to 1.5 σ). 
mIgG2b Fc mutations increase FcγRIV binding and affect N-glycan environment 
Only three amino acid differences at residues 300, 326 and 327 distinguish the BC, DE 
and FG loop regions of mIgG2c Fc from mIgG2b Fc and these likely contribute to the 
mFcγRIV binding interface (Fig 1E). Indeed, the FcγRIV binding affinities are similar but 
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mIgG2c binds with greater affinity than mIgG2b in either Fc glycoform studied here 
(Table 1). Residue I300 of mIgG2b Fc is positioned to perturb the DE loop organization 
and potentially reduce mIgG2b Fc affinity relative to mIgG2c. The two other differences 
at residues 326 and 327 do not appear to impact geometry of the FG loop backbone but 
may contribute to BC and DE loop motion by sidechain-mediated interactions (Fig 3D). 
The mIgG2b I300L mutation increased binding to FcγRIV by 1.2 to 1.6-fold for the 
truncated and complex-type glycoforms, respectively (Table 1). The inclusion of two FG 
loop mutations (mIgG2b I300L/K326R/D327A) increased binding from 2.2 to 2.3-fold.  
Changes in binding affinity mirrored NMR spectra of the mIgG2b Fc proteins, 
following N-glycan truncation (Fig 5). These spectra show the movement of anomeric 
peaks in an HSQC spectrum along a line towards the position of the same peak from 
the mIgG2c Fc protein. The reciprocal pattern of peak changes was observed with 
spectra of mIgG2c and the corresponding single L300I and triple L300I/R326K/A327D 
mutants, though the difference between single and triple mutants was less pronounced 
for the IgG2c mutations when compared to mIgG2b. The mutations decreased mIgG2c 
Fc binding by 1.8-fold for the truncated N-glycoform, and showed no difference for the 
complex-type N-glycoform outside of the error of the measurements (Table 1; on and 
off-rates for binding of the complex-type glycoforms are reported in Table S1).  
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Figure 5. 1H-13C HSQCs of anomeric (1)GlcNAc correlations from mouse IgG2b and 
mouse IgG2c Fc show near interconversion with amino acid substitution.  
It is worth noting that the FG loop mutations are at least 16 Å from the (1)GlcNAc 
residue, indicating changes to the FG loop affect the environment experienced by the N-
glycan. Such interactions likely involve contacts between the loops that transfer 
structural information along a non-bonded network. These data demonstrate the partial 
interconversion of mIgG2b and mIgG2c structure and receptor binding affinity, and 
confirm the link between NMR spectra features, in particular the anomeric correlation 
spectra, and loop stabilizing interactions. 
Discussion 
Here we demonstrate that mouse IgG2b and 2c have similar Fc structures for the 
complex-type N-glycoforms, however mIgG2c Fc binds FcγRIV with greater affinity. 
Differences in BC, DE and FG loop interactions account for the majority of the affinity 
difference. It is likely that other residues, not studied here including those at the 
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Cγ2/Cγ3 interface and hinge, contribute to the difference in binding between the triple 
mutant protein IgG2b and wild-type IgG2c Fc. Surprisingly, mIgG2c formed a stable and 
well-resolved structure once the N-glycan was truncated to a single asparagine-linked 
(1)GlcNAc residue, unlike other Fcs investigated to date. Without a structure of the 
mIgG:FcγRIV complex it is impossible to know which conformation is more relevant for 
receptor binding, however it is likely the conformation observed with the tighter-binding 
mIgG2c Fc displaying a complex-type N-glycan is the more relevant conformation.  
The effect of residue swaps on FcγRIV binding and the physical environment 
encompassing the anomeric (1)GlcNAc moiety highlights the link between DE loop 
stability and antibody function. Our group previously demonstrated that stabilizing the 
homologous loop in hIgG1 Fc on the µs-ms timescale increased receptor binding [18, 
20]. Mouse IgG2c Fc encodes a structure that is more conducive to tighter receptor 
binding in both N-glycoforms studied here. Based on the structural features, similarity of 
NMR and binding analyses it is likely mIgG2c interactions restrict DE loop motion, 
preorganizing the Fc for receptor binding. Our data do not directly address the 
amplitude or timescales of motion present in the Fc DE loops of N-glycans. 
 A comparison of structures from orthologous antibodies has the potential to 
identify the range of structural solutions selected through evolutionary processes. In 
addition to the basic understanding of structure/function/evolution relationships, a 
complete understanding of these mechanisms will aid development of antibodies with 
superior therapeutic properties. It is curious that hIgG1 Fc binds CD16A with lower 
affinity than these mouse Fcs bind the orthologous mouse receptor FcγRIV. Though the 
overall organizations of the molecules are comparable and expected given the common 
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origin, substantial differences in specific features emerged (Table S2). The C' strand of 
hIgG1 Fc (comparable to the D strand in mouse; Fig 1E) forms fewer stabilizing 
interactions with the E strand, resulting from distortion caused by a Pro residue at 
position 291 (Fig 6B). The distance between the 290 carbonyl oxygen and 303 amide 
nitrogen increased from 2.7 Å to 4.6 Å in human IgG1 Fc due to the Pro residue. The 
proline also shifts the register of the strand that is restored through a bulge at mIgG2c 
D295. Surprisingly, one reported model of mIgG2a forms a kink at position 291 similar 
to that of human IgG1 Fc [23] and another 2a model as well as 2b do not [24, 33]. The 
apparent structural plasticity of mIgG2a is surprising because the D strand sequence is 
identical to mIgG2c, suggesting other factors may contribute to structural differences in 
this area (Fig 1E).   
 
Figure 6. Mouse IgG2c and hIgG1 Fc show different strand and loop interactions. A. 
Mouse and human Fc fragments show a high degree of global similarity with an rmsd of 
0.7 Å. B. P291 of hIgG1 disrupts a beta sheet formation in the C' strand, and shifts the 
register by one residue that is relieved by a bulge at mIgG2c D295. Differences and 
similarities are identified in residues that mediate loop interactions in mIgG2c Fc (C) and 
hIgG1 Fc (D). 
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 More differences between hIgG1 Fc and mIgG2c Fc are found in the interactions 
between the BC, DE and FG loops. The impact of FG loop mutations on NMR spectra 
of the N-glycan clearly indicate a role for loop interactions in the mIgG2 Fc structures 
(Fig 5). Mouse IgG2c Fc shows a different organization around L300, including Van der 
Waals interactions with P271 and an ionic interaction between E268 and R293 (Fig 6C). 
The corresponding position in hIgG1 Fc (Y300) interacts with H268, P271, R292, R293 
and E294 (Fig 6D). Human IgG1 Fc H268 is positioned to form an ionic interaction with 
E294 that is similar to the E268:R293 bridge in mIgG2c, though the protonation state of 
the H268 sidechain is not known. Numerous single mutations to the hIgG1 hinge, BC, 
C'E and FG loops are reported at positions 265, 267, 270, 297, 298 327, or 329 that 
reduced CD16A binding (reviewed in [35]). Some hIgG1 Fc combinations mutants bind 
CD16A with greater affinity than the wild type sequence and include variations in the 
C'E and FG loops, including G236A/S293A/A330L/I332E [36] and 
F243L/R292P/Y300L/V305I/P396L [37]. It is, however, unclear what the effect of each 
amino acid substitution, in particular Y300L found in mIgG2c, is on receptor binding. 
It is unclear if the hIgG1 Fc C' strand destabilization is advantageous in the 
context of the human immune system, perhaps permanent stabilization through amino 
acid-amino acid contacts impedes the capacity for stabilizing intramolecular interactions 
between N-glycan and polypeptide residues to impact immune system function. For 
example, extending the hIgG1 Fc N-glycan increases intramolecular interactions 
between polypeptide and carbohydrate residues to reduce N-glycan motion, stabilize 
the C'E loop and increase receptor binding affinity [18, 20, 27]. There is ample evidence 
to implicate changes in hIgG1 N-glycan composition in multiple diseases and these data 
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indicate composition may be actively monitored and modified by the body to tune 
immune system function [38-44]. Though Würher and coworkers recently described the 
mouse antibody N-glycome, comparable studies linking glycan composition with 
immune system response are not available as of this writing [45]. 
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ACCESSED BY THE FC Γ RECEPTOR IIIA / CD16A N162–GLYCAN 
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Abstract 
Therapeutic monoclonal antibodies (mAbs) are largely based on the 
immunoglobulin G1 (IgG1) scaffold and many elicit a cytotoxic cell–mediated response 
by binding Fc γ receptors. Core fucosylation, a prevalent modification to the 
asparagine(N)–linked carbohydrate on the IgG1 crystallizable fragment (Fc), reduces Fc 
γ receptor IIIa (CD16a) binding affinity and mAb efficacy. We determined IgG1 Fc 
fucosylation reduced CD16a binding by 1.7 ± 0.1 kcal/mol when compared to 
afucosylated IgG1 Fc, however, CD16a N–glycan truncation decreased this penalty by 
1.2 ± 0.1 kcal/mol or 70%. Fc fucosylation restricted the manifold of conformations 
sampled by displacing the CD16a Asn162–glycan which impinges upon the linkage 
between the αmannose(1–6)βmannose residues and promoted contacts with the IgG 
Tyr296 residue. Fucosylation also impacted IgG1 Fc structure as indicated by changes 
in resonance frequencies and nuclear spin relaxation observed by solution NMR 
spectroscopy. The effects of fucosylation on IgG1 Fc may account for the remaining 0.5 
± 0.1 kcal/mol penalty of fucosylated IgG1 Fc binding CD16a when compared to 
afucosylated IgG1 Fc. Our results indicated the CD16a Asn162–glycan modulates 
antibody binding indirectly through reducing the volume sampled, as opposed to a direct 
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mechanism with intermolecular glycan-glycan contacts previously proposed to stabilize 
this system. Thus, antibody engineering to enhance intermolecular glycan-glycan 
contacts will likely provide limited improvement and future designs should maximize 
affinity by maintaining CD16a Asn162–glycan conformational heterogeneity. 
 
Figure 1. N–glycans are required for IgG1 Fc to bind CD16a. (A) Both IgG and CD16a 
are N–glycosylated and multiple N–glycans contribute to affinity. (B) Cartoon 
schematics for the IgG1 Fc and CD16a N–glycans; individual carbohydrate residues are 
defined in the inset. 
Introduction 
Antibodies bind to a pathogen or diseased tissue by recognizing specific surface 
features. The collection of antibodies on a target promotes the clustering of antibody 
receptors on the surface of leucocytes, triggering cell activation and a protective 
response 1-3. Therapeutic monoclonal antibodies (mAbs) of the immunoglobulin G (IgG) 
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isotype are developed to target specific features of a cancerous tissue or dysregulated 
immune cells through antigen binding fragments (Fabs) and bind multiple types of Fc γ 
receptors (FcγRs) expressed on leukocytes with the crystallizable fragment (Fc) to elicit 
a cell–mediated response to treat leukemia, lymphomas, tumors, autoimmune disease 
and other diseases (Figure 1). The efficacy of these therapies is likely directly related to 
the affinity between FcγRIIIa / CD16a and the antibody, triggering an antibody–
dependent cell–mediated cytotoxic response (ADCC) 4, 5. Thus, treatment efficacy will 
benefit from mAbs with enhanced affinity for CD16a. 
 A major advance in mAb development came when Shields et al. discovered 
antibodies lacking a prevalent post–translational modification to the conserved and 
essential Fc Asn297–linked carbohydrate (N–glycan), core fucosylation, bound CD16a 
with 50-fold greater affinity than typical human IgG1s (~95% core fucosylated) and 
elicited ADCC at lower concentrations 6-8. This discovery stimulated the development of 
glycoengineered mAbs with higher affinity for CD16a that differ only in carbohydrate 
composition 9, 10. The body also modulates antibody fucosylation: Kapur et al. observed 
patients with severe neonatal alloimmune thrombocytopenia produced anti–platelet 
antibodies with very low fucosylation (<10%); furthermore, the degree of antigen–
specific anti–platelet antibody fucosylation correlated inversely with immune response 
and disease severity 11. For these reasons it is important to determine how tuning the 
IgG1 Fc N–glycan composition imparts a relevant increase in CD16a binding affinity. 
 The composition of bulk serum IgG1 Fc N–glycans is widely studied as a 
biomarker for disease or aging (12-15, among others) and the discovery of antigen–
specific IgG N–glycan composition, including fucosylation levels <10%, indicates the 
58 
 
 
possibility of glycoengineering conducted by plasma cells or the clonal selection 
process to advantage responses to certain antibodies 11, 16-19. The predominant IgG1 Fc 
N–glycans in human serum are of a biantennary complex–type with variable levels of 
galactose and N–acetylneuraminic acid at the non–reducing termini (Figure 1; 20). The 
Fc N–glycan restricts conformational mobility of the Fc C'E loop which contains the 
Asn297 site of glycosylation and forms polypeptide–polypeptide contacts with FcγRs to 
form a complex with relatively high affinity, depending on the –µM; 21-23).  
CD16a is likewise glycosylated, with five N–glycosylation sites on the 
extracellular antibody binding domain. Our lab determined that CD16a isolated from NK 
cells contains a substantial amount of under-processed oligomannose (23%) and 
hybrid-type glycans (22%) glycoforms with far less complex-type (55%) than CD16a 
expressed in human embryonic kidney 293F cells (73-82% complex-type; 24). 
Furthermore, CD16a displaying Man5 oligomannose N-glycans bound IgG1 Fc 12-fold 
tighter than CD16a with complex-type N-glycans 24. Of the five CD16a N-glycans, two, 
at Asn45 and Asn162, impact IgG1 binding affinity. Shibata–Koyama et al. reported the 
Asn45–glycan reduced antibody binding, and Ferrara et al. reported that the Asn162–
glycan was important for high affinity antibody binding and sensed the presence of 
antibody fucosylation 25, 26. The presence of a fucose residue on IgG1 Fc did not create 
a steric clash to disrupt the interface formed by polypeptide residues nor did fucose 
impart a change to the IgG1 Fc structure. Using X–ray crystallography, two groups 
determined similar structures of CD16a in complex with afucosylated IgG1 Fc that 
showed the CD16a Asn162–glycan contacted the IgG1 Fc Asn297–glycan 27, 28. These 
authors suggested IgG1 lacking the core fucose residue bound CD16a with higher 
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affinity than fucosylated IgG1 because the CD16a Asn162–glycan formed stabilizing 
contacts with the IgG1 Fc Asn297 glycan that were disrupted by the fucose residue. 
The identification of stabilizing carbohydrate–carbohydrate contacts suggested a 
novel mechanism for receptor–ligand interactions capable of sensing ligand N–glycan 
composition. Furthermore, the nature of these observed intermolecular carbohydrate–
carbohydrate interactions were unlike other examples and consisted of mostly 
stabilizing H–bonds with some van der Waals contacts 27, 28. Carbohydrate polymers 
contain the most thoroughly studied carbohydrate–carbohydrate interactions and are 
formed by a mixture of H–bonds and hydrophobic interactions. Hydrophobic 
interactions, however, are predominant and provide >80% of the energy to stabilize 
crystalline cellulose, a β(1–4)glucose polymer, and chitin, a β(1–4) N–acetylglucosamine 
reside (GlcNAc) polymer 29, 30. A greater degree of stabilization from H–bonds forms A–
amylose, an α(1–4)glucose polymer, however, A–amylose contains water in the crystal 
and denatures at a far lower temperature than cellulose or chitin, which completely 
exclude water upon crystallization 31. N–glycan stabilization, when observed, occurs 
largely through hydrophobic forces 32, including dispersion forces 33. One example of N-
glycan stabilization is observed with IgG1 Fc. Mobility of the IgG1 Fc N–glycan is 
restricted by interactions with side chains from two aromatic residues, F241 and F243, 
and restricting N–glycan motion increases CD16a binding 21. The appearance of 
carbohydrate-carbohydrate interactions in structures of the CD16a:IgG1 Fc complex 
were surprising based on the aforementioned precedents. We began by investigating 
the energetic contribution of intermolecular carbohydrate–carbohydrate interactions to 
the CD16a:IgG1 Fc complex.  
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Results 
Crystallography of the IgG1 Fc:CD16a complex 
Previous X-ray diffraction studies identified a stabilizing interaction between the 
CD16a (N38Q/N74Q/N169Q) Asn162–glycan and the IgG1 Fc Asn297–glycan. We 
expect that if intermolecular glycan–glycan contacts are an important stabilizing feature 
of the IgG Fc:CD16a interaction that contacts will be preserved in all structures with 
glycosylated CD16a. Furthermore, we expect the tightest-binding glycoform would be 
stabilized by glycan-glycan interactions. We crystallized CD16a (N38Q/N74Q/N169Q) 
with Man5 oligomannose N-glycans to mimic a glycoform that was found on CD16a 
expressed by human NK cells and bound afucosylated IgG1 Fc tighter than CD16a with 
either Man9 oligomannose N-glycans or complex-type N-glycans (Table 1, 
Supplemental Figure 1 and 24). The crystallization of Man5 CD16a is in contrast to 
CD16a with Man9 oligomannose N–glycans 27 or complex–type N-glycans 28 studied 
previously. Crystals of the afucosylated IgG1 Fc (with G0, G1 and G2 N–
glycans):CD16a(Man5) complex diffracted to 2.26 Å in the C 2 space group with high 
completeness (Supplemental Table 1). Molecular replacement revealed a high quality 
structural model with similar refinement statistics to the previous reports (Rwork 0.192, 
Rfree 0.237; Figure 2). This new model proved highly similar to previously determined 
models with RMSD values of 0.94 (PDB id 3sgj 27), 1.03 (3sgk 27), and 0.96 Å (3ay4 28) 
with small differences in the orientation of CD16a domain I which does not contact the 
Fc. In contrast to the previous reports, only the (1)GlcNAc residue of the CD16a Asn162 
N–glycan appeared in density maps (Figure 2A). It was surprising that we did not 
61 
 
 
observe density for the distal portions of the Asn162–glycan including the (2)GlcNAc 
and (3)Man residues if these residues form important stabilizing contacts.  
Table 1. SPR analysis of different CD16a glycoforms. Glycoform analysis of each 
material is shown in Supplemental Figure 1. (Performed by GPS) 
 
fuc. IgG1 Fc 
 
afuc. IgG1 Fc  
CD16a N-glycoform KD (nM) ± err KD (nM) ± err 
Man5 57 9 2.5 0.2 
Man9 64 8 4 0.7 
complex-type 245 30 38 9.0 
 
 
Figure 2. Structure of CD16a N38Q/N74Q/N169Q (Man5) in complex with afucosylated 
IgG1 Fc. (A) The binding interface shows an interaction between the Fc Asn297–glycan 
and clear density around the (1)GlcNAc residue from the CD16a Asn162–glycan scaled 
to σ=1.5. (B) An overall view of the complex. (C) The Asn45 glycan of CD16a shows 
clear density for only the (1)GlcNAc residue scaled to σ =1.0. (Performed by GPS and 
AMM) 
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Two CD16a N–glycans impact affinity 
Our binding analyses confirmed the role of the CD16a Asn162–glycan: replacing 
Asn162 with Gln to prevent N–glycosylation at position 162 decreased affinity for IgG1 
Fc with the G0F N–glycan by 3.5–fold (Table 2). Affinity improved after removing the 
Asn38, Asn74 and Asn169 N–glycans. Shibata–Koyama et al. reported that removing 
the Asn45–glycan from CD16a expressed with complex-type N-glycans enhanced 
binding 26 but we found removing the Asn45–glycan from CD16a expressed with Man5 
N-glycans decreased binding, and the N45Q/N162Q CD16a variant bound with even 
less affinity for IgG1 Fc than either singly–mutated CD16a (Table 2). It is possible that 
differences in CD16a glycan composition are responsible for the opposing reports on 
the contribution of the Asn45-glycan to binding; it was recently established that CD16a 
N-glycan composition impacts affinity (Table 1 and 24, 34). Recent solution NMR and 
molecular dynamics studies showed that the Asn45-glycan(Man5) stabilizes CD16a 
through intramolecular protein–carbohydrate interactions, likely contributing to antibody 
binding 35. Complex-type N-glycans likely have a similar capacity to impact CD16a 
structure, though it is unclear how differences in N-glycan composition impact antibody 
binding. 
Truncating the CD16a N-glycans reduces the impact of IgG1 Fc fucosylation – 
Multiple groups reported that distal residues of the Asn162–glycan, notably the (2, 3 and 
4)Man residues, are essential for high affinity binding of afucosylated IgG1 Fc through 
contacts with the Fc Asn297–glycan 25, 26. If the CD16a Asn162–glycan forms stabilizing 
contacts with Fc, truncating the CD16a N–glycan to remove these residues should 
reduce affinity. In fact, truncating the N–glycans of either wild–type CD16a or the 
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N38Q/N74Q/N169Q CD16a variant to a single (1)GlcNAc residue increased binding to 
the afucosylated IgG1 Fc glycoforms by 1.1 to 1.4 fold (Table 3). This result indicated 
that CD16a with truncated N-glycans bound with comparable affinity to afucosylated 
IgG1 Fc as CD16a with complete Man5 N-glycans because the distal portions of the 
Asn162 and Asn45-glycans had a negligible or small negative impact on binding affinity.  
Table 2. SPR analysis shows CD16a Asn162 and Asn45 N–glycans are critical for 
binding IgG1 Fc. (Performed by GPS) 
 
Fc G0F 
 
CD16a KD (nM) ± err 
wt 18 1 
N38Q/N74Q/N169Q 11 1 
N45Q 32 4 
N162Q 64 3 
N45Q/N162Q 290 10 
N38Q/N45Q/N74Q/N169Q 360 40 
 
Table 3. CD16a N–glycan truncation enhances affinity in SPR experiments and reduces 
the impact of IgG1 Fc fucosylation. (Performed by GPS) 
 
Fc G0F 
 
Fc G2F 
 
Fc G0 
 
CD16a KD (nM) ± err KD (nM) ± err KD (nM) ± err 
wt 18 1 9.9 0.3 2.4 0.2 
wt–EF1* 3.7 0.2 2.0 0.1 1.7 0.1 
N38Q/N74Q/N169Q 11 1 5.2 0.5 1.4 0.3 
N38Q/N74Q/N169Q–EF1 2.9 0.4 1.6 0.1 1.3 0.1 
*CD16a following treatment with Endoglycosidase F1 
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It is formally possible that N-glycan truncation allowed CD16a to sample 
conformations that bound IgG1 Fc with higher affinity, and overcome the impact of 
removing residues that contribute to binding through stabilizing intermolecular N-glycan 
contacts. NMR spectra of 15N[Tyr,Phe]-CD16a with either Man5 or truncated (1)GlcNAc 
N-glycans reveals 1H and15N and are all less than 0.02 and 0.2 ppm, respectively, as 
shown in Figure 3. Furthermore, recent evidence from our group demonstrated that 
endoglycosidase F1 treatment of CD16a did not alter the chemical environment 
experienced by the (1)GlcNAc C1 and H1 nuclei in contrast to trypsin proteolysis which 
dramatically altered the environment 35. Therefore, N–glycan truncation does not impact 
CD16a structure proximal to the Phe, Tyr or (1)GlcNAc residues and it is unlikely that N-
glycan truncation substantially alters other aspects of CD16a structure. Expression of 
CD16a variants containing a single N–glycan failed to provide enough material for 
binding affinity measurements. 
If the CD16a Asn162–glycan forms stabilizing contacts with afucosylated Fc and 
core fucosylation of Fc disrupts those contacts, truncating the CD16a N–glycan to 
remove these residues should reduce affinity for afucosylated Fc to a value that is 
expected to be similar to binding fucosylated Fc. Furthermore, truncating the CD16a N-
glycan should not impact binding fucosylated IgG1 Fc. However, CD16a N-glycan 
truncation slightly increased affinity towards afucosylated IgG1 Fc as noted and 
dramatically increased affinity towards fucosylated IgG1 Fc from three to five-fold (Table 
3). As a result, truncating the CD16a N-glycans reduced the impact of IgG1 Fc core 
fucosylation from an eight-fold decrease in affinity upon fucosylation (G0 v. G0F for 
binding CD16a with Man5 N-glycans; Table 3) to a two-fold decrease (G0 v. G0F for 
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binding CD16a with truncated N-glycans). This result further indicates residues on distal 
portions of the CD16a N162-glycan sense the fucosylation status of IgG1 Fc and reduce 
affinity towards fucosylated IgG1 Fc. Re-examination of the data in Table 1 for 
afucosylated IgG1 Fc are consistent with this interpretation, the CD16a with the larger 
Man9 oligomannose N-glycans binds slightly weaker than CD16a with the smaller Man5 
N-glycans (errors for the fucosylated IgG1 Fc species are overlapping and do not allow 
a similar comparison). 
 
Figure 3. Predominant conformations sampled by CD16a are unaltered by N-
glycan truncation. A 1H-15N heteronuclear single quantum coherence spectrum of 
15N[Tyr,Phe]-CD16a. Seventeen peaks are visible and correspond to eight Tyr and eight 
Phe residues in the CD16a construct. (Performed by GPS) 
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 The preceding binding experiments utilized pure IgG1 Fc N-glycoforms, but in 
serum the glycoforms vary to a greater degree. To evaluate the impact of mixed N-
glycan species, we prepared two pools of IgG1 Fc to compare the major species found 
in human sera: fucosylated IgG1 Fc with predominantly G0F/G1F/G2F and afucosylated 
IgG1 Fc with the G0F/G1F/G2F. Galactose residues were evenly distributed and IgG1 
Fc contained N–glycans with one to four galactose residues (Supplemental Figure 2). 
Binding measurements observed with SPR and ITC using these heterogeneous 
materials were comparable to those collected with pure N-glycoforms and revealed that 
CD16a N-glycan truncation had a minimal impact on CD16a binding to afucosylated 
IgG1 Fc and increased binding to fucosylated IgG1 Fc by 1.7 ± 0.1 kcal/mol (Figure 4 
and Supplemental Figures 3&4). Though the ITC experiments also provided estimates 
of entropy and enthalpy, it is difficult to determine from these experiments how 
conformational entropy of the CD16a N162-glycan contributions to binding fucosylated 
or afucosylated antibody because the CD16a used in these measurements displayed 
five N-glycans and it is not possible to separate the contribution from conformational or 
solvent entropy. 
Simulation of the CD16a complex with IgG1 Fc – The preceding binding and 
structural analyses represent an important view of CD16a function but do not provide 
detailed information regarding mechanism at the atomic scale. X–ray crystallography 
elucidates atomic–level detail, but offers limited insight into fundamental, functionally–
relevant motions. Computational simulations bridge this gap to provide a view into an 
ensemble of accessible conformations with atomic precision. 
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All–atom, solvated simulations of the CD16a:IgG1 Fc complex revealed motion of 
protein and carbohydrate components using IgG1 Fc Asn297–glycans with and without 
core fucosylation. CD16a N–glycan coordinates from X–ray crystallography for 
fucosylated and afucosylated complexes with significant portions of the carbohydrates 
observed provided starting positions for the simulations (pdbs 3sgj and 3sgk 27). Protein 
2°, 3° and 4° structural elements showed limited conformational variability in the 
simulations, likely reflecting the stability of CD16a (N38Q/N74Q/N169Q) and IgG1 Fc, 
tight binding and the simulation timescales (0.25 – 1 µs; Supplemental Figure 5). The 
CD16a Asn162–glycan, however, sampled a large 26,700 Å3 volume in a simulation of 
unliganded CD16a (Figure 5). 
The sampled volume diminished by 60% upon complexation with afucosylated IgG1 Fc. 
The addition of core fucose residues to the IgG1 Fc N–glycan reduced the volume 
sampled by an additional 16%, forming a cavity around the (0)fucose residue and the 
Asn162 N–glycan shifted towards the opposite Fc chain. This conformation sampling is 
unlike the CD16a Asn45–glycan that formed extensive interactions with the CD16a 
polypeptide surface and sampled a smaller area with much less variability between 
ligand states (average of 7,600 Å3; Figure 5). A duplicate set of 250 ns simulations 
revealed comparable results. RMSD values for each N–glycan residue showed a similar 
trend and support these observations (Supplemental Figure 6). This result indicated the 
(0)fucose residue altered the preferred conformations sampled by the Asn162 glycan, 
introducing a fucose–dependent energetic penalty upon binding IgG1 Fc. 
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Figure 4. Representative SPR sensograms for CD16a N–glycoforms binding IgG1 Fc. 
Response units from each sensogram were extracted once binding reached a steady 
state level to generate the binding curves shown on the bottom sections of each panel. 
Binding curves result from fitting the observed data shown as individual points in these 
plots. (Performed by DJF) 
 Conformations sampled by the Asn162–glycan demonstrated a role for glycan 
conformational sampling in antibody binding. Each glycosidic linkage sampled a defined 
set of rotamers; rotamers for each linkage were defined using a 1 µs simulation of the 
Asn162–glycan on a five–residue CD16a glycopeptide angle (rotamers are defined in 
Supplemental Figure 7). This glycopeptide glycan sampled the greatest number of 
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unique conformations (305). Sampled conformations decreased to 226 conformations 
resulting from steric constraints once attached to the CD16a polypeptide (the rotamer 
binning approach accounted for 99.95% of all observations). The N162-glycan on 
CD16a in complex with afucosylated IgG1 Fc sampled 103 unique states (99.76%), and 
the glycan on CD16a in complex with fucosylated IgG1 Fc sampled 75 unique states 
(100.00%). GlcNAc and mannose in the pyranose form behave largely as rigid units, 
with N–glycan flexibility limited to glycosidic linkages between residues characterized by 
 and  dihedral angles. Linkages to primary alcohols (on the C6 of mannose) provide 
an additional degree of freedom with and  angles. Thus, differences in N–glycan 
conformation will be reflected in these dihedral angles. 
Dihedral angles sampled by multiple residues in the Asn162–glycan shifted 
following binding to IgG1 Fc (Figure 6 & Supplemental Figure 7). One linkage, however, 
accounted for the majority of differences between binding afucosylated and fucosylated 
IgG1 Fc:  and  between the (4') mannose and (3) mannose residues (Figure 6 & 
Supplemental Figure 7-5). Though N162-glycans from all simulations sampled identical 
conformations of this linkage, the proportions differed. This became evident after 
analyzing the N162-glycan conformations sampled in the simulation of CD16a that 
sampled a predominant conformation (#5, 81%) that was sampled at a lower rate (36%) 
in the simulation of the complex with afucosylated IgG1 Fc and less still (28%) with 
fusocylated IgG1 Fc (Figure 6 and Supplemental Table 2). We believe this represents a 
penalty for burying the N162-glycan upon complexation that becomes exacerbated with 
antibody fucosylation, further restricting the available volume. A compensatory change 
is evident from the increased sampling of conformation #1 in the simulation with 
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fucosylated IgG1 Fc (65%) compared to afucosylated (35%) that is lightly sampled in 
the simulation of CD16a alone (4%). The Fc Asn297–(0)fucose residue was proximal to 
the CD16a Asn162 (2)GlcNAc and (3)Man residues (pdb–3sgj; 27). The conformational 
restriction occurred from a steric clash between the fucose and (3)Man residues, 
displacing the entire Asn162 glycan to restrict conformations sampled by the (3)-(4’) 
linkage (Supplemental Figure 8). Fucosylation did not appear to impact the mobility of 
the IgG1 Fc Asn297–glycan when in complex with CD16a to a large extent 
(Supplemental Figure 9). A second set of 250 ns simulations revealed comparable 
results. 
 
Figure 5. Molecular dynamics simulations of CD16a reveal the space sampled by 
CD16a N–glycans. The top row shows a grey surface representation for the area 
samples in simulations for the CD16a Asn162 N–glycan. The bottom row shows the 
same features for the CD16a Asn45 N–glycan. The volumes sampled by each glycan 
are indicated. (Performed by DJF) 
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Figure 6. A linkage in the CD16a Asn162–glycan explains the conformation difference 
between binding afucosylated Fc and fucosylated Fc. The area for each color in the 
discs represents the proportion of a distinct conformational state sampled by the 
Asn162–glycan in all-atom simulations. The dashed box highlights differences in 
conformations sampled by the linkage connecting the 3 and 4' mannose residues. 
Conformation states for each linkage are defined in Supplemental Figure 7. (Performed 
by DJF)  
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 Few contacts between the CD16a Asn162–glycan and IgG1 Fc Asn297–glycans 
formed during the simulations. An analysis of H–bond interactions from all snapshots of 
the simulations showed no single interchain Asn162–glycan/Asn297–glycan contact 
formed for more than 20% of the experiment (Supplemental Figure 10, orange bars). 
Significant intrachain Asn162–glycan contacts, including (1)GlcNAc O3–(2)GlcNAc O5 
and (2)GlcNAc O3–(3)Man O5, stabilized the first three N–glycan residues and are 
consistent with contacts in (1–4) linked oligosaccharides including cellulose 
(Supplemental Figure 10, yellow bars; 30). It is possible that the simulation parameters 
treated van der Waals interactions in an inappropriate manner, leading to a loss of 
Asn162–glycan stabilization. However, the IgG1 Fc–Asn297 N–glycan that is stabilized 
primarily through van der Waals interactions against the surface of the Fc Cγ2 domain 
21, 36 formed the expected long–lasting interactions with IgG1 Fc residues F241 and 
F243 (Supplemental Figure 9).  
Accelerated molecular dynamics simulations 
One limitation of all-atom simulations for large complexes is an inability to sample 
extended timescales using conventional sampling and desktop computational 
resources, limiting the ability to observe motions that might occur on the time scale of 
hundreds of ns to tens of µs. We performed accelerated molecular dynamics 
simulations (aMD) using the same starting coordinates as the previous 250 ns all-atom 
simulations to allow for the sampling of a broader conformation range, if the simulation 
time for the previous examples were limiting. AMD reduces the average potential and 
dihedral energies and allows the evolution of a single copy of the molecule of interest 
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without any prior knowledge of conformations, energy barriers or saddle points 37. 
Reducing barrier energies, however, may promote the formation of unreasonable or 
unlikely conformations. During the simulation of fucosylated IgG1 Fc in complex with 
CD16a, the IgG1 Fc Cγ3 domains adopted an unexpected, extended conformation. 
Though this may occur in vitro, the Cγ3 dimer is the most stable region of IgG1 Fc and 
unfolded conformations are likely sampled rarely (Supplemental Figure 11). Based on 
this result, we limited our analyses of the aMD simulations to the first 5000 sampled 
steps of each simulation that displayed well-defined protein secondary and tertiary 
structural elements. 
Interestingly, the CD16a N162-glycan did not access any new states linking 
Man5 N-glycan monosaccharide residues indicating that the conventional MD approach 
captured a high degree of rotation around each individual linkage and that the rotamer 
binning approach was sufficient to capture appropriate local N-glycan conformational 
states from the aMD simulations. However, the N162-glycan did sample new 
combinations of linkage orientations. The N162-glycan from CD16a in complex with 
afucosylated and fucosylated IgG1 Fc accessed 517 and 570 distinct states, 
respectively. Furthermore, the rotamer binning approach, as applied to the aMD 
simulations accounted for the majority of observations (98.58% and 99.44%, 
respectively). The predominant conformations observed at most linkages were similar 
between the simulations that included fucosylated IgG1 Fc and afucosylated IgG1 Fc 
with the exception of the  and  dihedral angles between the (4') mannose and (3) 
mannose residues. For these dihedral angles, differences between the two simulations 
emerged. Though the precise percentage of each population was different when 
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comparing conventional and aMD simulations of similarly glycosylated IgG1 Fc, the 
aMD simulations recapitulated differences between fucosylated and afucosylated IgG1 
Fc. It is worthwhile to highlight another linkage in the glycan, between the (5'') 
mannose and (4') mannose residues, has an identical 1-6 linkage but does not 
contact IgG1 Fc. In this instance there is no discernable difference between simulations 
with fucosylated or afucosylated IgG1 Fc.  
 It is unclear why two independent groups observed intermolecular N–glycan 
contacts by X–ray crystallography and we observed neither corresponding electron 
density nor Asn162–glycan dependent stabilization upon binding by SPR, ITC or in the 
computational simulations. It is possible the conformation of the CD16a Asn162–glycan 
differed based on composition and crystal contacts restricted conformations in the 
previous cases. It is also possible stabilizing interactions are formed from low energy 
conformations and magnified by cryopreservation or the effects of these contacts are 
lessened in solution at physiological temperature and sampled only transiently during 
the simulations. 
The role of fucose in IgG1 Fc structure 
The presence of a fucose residue reduced G for CD16a(Man5) binding IgG1 Fc 
by 1.7 ± 0.1 kcal/mol with the predominant, but not entire, contribution attributable to the 
CD16a Asn162–glycan (1.2 ± 0.1 kcal/mol; Supplemental Figures 3 & 4). Thus, an 
additional, unidentified feature other than the Asn162–glycan must contribute the 
remaining 0.5 ± 0.1 kcal/mol. Matsumiya and coworkers noted that fucosylating IgG1 Fc 
changed resonance frequencies for Tyr296 and Tyr300 in the Fc C'E loop, but not six 
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other Tyr residues in other Fc regions, indicating minor Fc structural changes occur 
upon fucosylation 38. We also observed IgG1 Fc fucosylation–dependent effects on 
binding to CD32, which does not contain an N–glycan at a position analogous to CD16a 
Asn162 but does bind in a similar mode 23. These results indicated IgG1 Fc fucosylation 
impacts IgG1 Fc structure in a region and in a manner that is poised to impact FcγR 
binding. 
 We probed the effect of core fucosylation on IgG1 Fc structure and motion in the 
absence of receptor by observing the resonance frequencies of (1)GlcNAc and 
(0)fucose nuclei with solution NMR spectroscopy. IgG1 Fc with a truncated N–glycan 
makes an ideal glycoform to study with solution NMR because this form is sensitive to 
fucosylation and will lead to simpler spectra of IgG1 Fc expressed in the presence of 
[13C]–glucose 22, 39, 40.  IgG1 Fc with a single (1)GlcNAc residue at Asn297 showed a 
clear peak for the anomeric 1H–13C correlation and the other expected correlations in a 
1H–13C HSQC spectrum of IgG1 Fc expressed in the presence of [13CU]–glucose (Figure 
7 & Supplemental Figure 12). A similar experiment using IgG1 Fc truncated to an N–
glycan composition consisting of a (1)GlcNAc and (0)fucose residue revealed similar 
peaks that were displaced. It is possible that the chemical modification of the (1)GlcNAc 
residue with a fucose addition explained these changes in the spectra by changing 
through–bond interactions. However, treating the samples with trypsin to destroy 
intramolecular glycan/polypeptide contacts but preserve the (1)GlcNAc–(0)fucose 
glycosidic linkage showed very slight differences in resonance frequency position, in 
particular for the anomeric correlations, indicating the addition of a fucose residue 
altered the chemical environment of the (1)GlcNAc H1 and C1 nuclei by perturbing 
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interactions with the Fc polypeptide. Correlations of the anomeric nuclei are most 
sensitive to intramolecular glycan/polypeptide interactions due to the proximity to the 
glycosidic linkage to Asn297, the predominant rotatable moiety in this carbohydrate 
residue. Furthermore, the linewidth of the IgG1 Fc (1)GlcNAc H1/C1 correlation with 
fucose attached was broader than the linewidth for the afucosylated IgG1 Fc (1)GlcNAc 
H1/C1 correlation, indicating the possibility of different rates of motion associated with 
the (1)GlcNAc residues. 
 
Figure 7. 1H–13C HSQCs of the IgG1 Fc Asn297 (1)GlcNAc H1 show changes in the 
observed resonance frequency as a result of fucosylation. The effect of protein structure 
was removed by trypsin–catalyzed cleavage (shown in the red and green contours). 
(Performed by DJF) 
 Measurements of relaxation rates for signals in an NMR experiment may provide 
information regarding N–glycan motion faster than the rotational correlation time (expect 
~20 ns 41; R1 and R2) or in the µs–ms timescale (R2 only; see 42 and references therein 
for a review). Measurements of R1 and R2 for the (1)GlcNAc C4 nucleus were consistent 
with different rates of motion between fucosylated and afucosylated samples. The R1 for 
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afucosylated Fc was greater than fucosylated Fc (1.28 ± 0.01 s–1 vs. 1.08 ± 0.05 s–1) 
and smaller for R2 (51 ± 4 s–1 vs. 73 ± 6 s–1). These changes are consistent with faster 
motion of the (1)GlcNAc residue on the ns timescale without fucose. Slow µs–ms 
motions also appear to contribute to the unexpectedly large R2 values (based on the R1 
values). These results are consistent with previous measurements of nuclei in galactose 
and sialic acid residues on the non–reducing termini of IgG1 Fc 41, 43. 
 The results from NMR experiments indicated fucosylation slows the motion of the 
(1)GlcNAc residue, further reducing the binding to CD16a. This result is consistent with 
the previous report revealing changes of Fc backbone amide peaks resulting from N–
glycan fucosylation 38. From these spectra it is difficult to determine which Fc residues 
are impacted by fucose, however, Matsumiya et al. suggest the conformation of Tyr296 
is important for CD16a binding and is in a position to be affected by the (0)fucose 
residue; Tyr296 residue is immediately adjacent to the Asn297 site of N–glycan 
attachment 38.  
Discussion 
Here we present a model for the role of fucose in antibody/CD16 interactions: 
IgG1 Fc fucose disrupts the conformations sampled by the CD16a Asn162–glycan, 
exerting a negative impact of CD16a affinity for fucosylated IgG1 Fc relative to 
afucosylated IgG1. It is clear the CD16a Asn162–glycan senses IgG1 Fc fucosylation; 
truncating the CD16a N–glycans increases binding to fucosylated IgG1 Fc and removes 
the sensitivity to core fucosylation of the IgG1 Fc Asn297–glycan. Fucose has 
additional, though less significant, impacts on IgG1 Fc structure and motion, slowing the 
motion of the Asn297 glycan and further reducing CD16a binding. Our model indicates 
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antibody engineering efforts to enhance the intermolecular carbohydrate–carbohydrate 
contacts will likely have limited impact, and engineering IgG to avoid impingement on 
the area sampled by the CD16a Asn162–glycan in complex or to truncate the Asn162–
glycan is a promising pathway to increase affinity for CD16a. 
The results presented in this manuscript are generally consistent with multiple 
aspects of the previous studies on the IgG1 Fc:CD16a complex that IgG1 Fc 
fucosylation disrupts the CD16a N162-glycan, leading to a reduction in binding affinity. 
Here we propose a different mechanism. The previous studies reported antibody 
fucosylation disrupted a single conformation of the CD16a N162-glycan conformation 27, 
28. Based on our results we believe that antibody fucosylation restricts the manifold of 
conformations sampled by the CD16a N162-glycan with no state forming extensive 
intermolecular contacts with IgG1 Fc. Another recent report applied replica exchange 
MD simulations to study the complex of IgG1 Fc with CD16a. Sakae et al. showed that 
the Man3 and Man4 residues of the CD16a N162-glycan, in a complex-type biantennary 
glycoform, were consistently 1-3 Å closer to the IgG1 Fc (1)GlcNAc residue when the 
IgG1 Fc fucose residue was absent, though they did not report Van der Waals or 
hydrogen-bond contacts formed in the simulations nor whether these contacts were 
maintained in a way that would be expected for a stabilizing interaction 44. This 
approach is consistent with our simulations as the IgG1 Fc fucose and Y296 residues 
together displace the N162-glycan (Supplemental Figure 8). Furthermore, Sakae et al. 
also showed that the N162-glycan on the CD16a complex with fucosylated IgG1 Fc 
sampled greater volume and had a greater RMSF value than the N162-glycan on the 
CD16a:fucosylated IgG1 Fc complex. Thus, the N162 glycan in the simulations by 
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Sakae et al. and introduced in this manuscript revealed that the N162 N-glycan is highly 
mobile in the CD16a:IgG1 Fc complex. Sakae et al. concluded that IgG1 Fc fucosylation 
increased N-glycan conformational fluctuation for a complex-type biantennary CD16a 
N162-glycan. Our results do not allow a definitive evaluation of this hypothesis; we 
observed more conformations sampled by the CD16a N162-glycan in aMD simulations 
with fucosylated compared to afucosylated IgG1 Fc (570 v. 517) but less with the 
conventional MD approach (75 v. 103). Here we determined that IgG1 fucosylation 
reduces the volume available to the CD16a N162-glycan in complex with IgG1 Fc, and 
perturbs the conformations sampled by a Man5 N-glycan. 
 The activity of the CD16a Asn162–glycan is the second example of an N–glycan 
indirectly modulating ligand binding. Adding residues at the non–reducing termini of the 
IgG1 Fc Asn297–glycan increases CD16a binding by stabilizing the motion of the 
carbohydrate and the Fc C'E loop residues at the binding interface 21. Both the CD16a 
Asn162–glycan and the IgG1 Fc Asn297–glycan influence binding, but neither is directly 
bound by the other protein, as is the case for the recognition of carbohydrate ligands by 
a lectin. These types of intermolecular interactions are challenging to identify. However, 
N–glycans are pervasive modifications and important interactions involving N-glycans 
are potentially common features of glycoprotein interactions. Changing carbohydrate 
composition is potentially widely utilized and offers the capacity for a rapid and tunable 
response, in this case modifying the threshold of an immune response that does not 
require changes to protein coding genes. 
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Materials and Methods 
All materials were purchased from Sigma–Aldrich unless otherwise specified.  
Protein expression and purification (performed by DJF and GPS)  
Human IgG1 Fc (residues 216–447) was expressed using the HEK293F cells 
grown in Freestyle293 medium (Life Technologies) as previously described 21. 
Afucosylated IgG1 Fc was expressed using culture medium supplemented with 250 μM 
2–deoxy–2–fluoro–L–fucose (Santa Cruz Biotech)45. Plasmids encoding the CD16a 
variants Asn45Q, Asn162Q, Asn45Q/Asn162Q, N38Q/N74Q/N169Q were prepared 
according to the QuickChange protocol (Agilent Technologies) and confirmed by DNA 
sequencing (ISU DNA facility). CD16a (residues 19–193, V158 allotype) was expressed 
using the HEK293F or HEK293S(lec1–/–) cell lines with Freestyle293 medium (Life 
Technologies) as previously described 21, 39. CD16a with Man9 oligomannose N-glycans 
was expressed by supplementing the expression medium with 5 µM kifunensine 
(Cayman Chemical). Following purification, proteins were exchanged into 20 mM 3–
morpholinopropane–1–sulfonic acid (MOPS), 100 mM sodium chloride, pH 7.2. CD16a 
was stored at –80 °C in 25% glycerol. 13C labeled protein was prepared by 
supplementing the expression medium with [13C6]–D–glucose as previously described 
39. CD16a N-glycans were analyzed following derivatization with procainamide and 
HILIC-ESI-MS as previously described 24. 
IgG1 Fc N–glycan remodeling in-vitro (performed by GPS) 
IgG1 Fc glycovariants with intact homogenous N–glycans (G0, G0F and G2F) 
were prepared and purified as described previously 23. Agalactosylated IgG1 Fc (G0F) 
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was prepared by adding 5 μL of 3 U/mL Streptococcus pneumoniae β–1,4 
galactosidase to purified glycoprotein (2 mg at 12.5 mg/mL) and incubated overnight in 
the dark at room temperature. Afucosylated IgG1 Fc (G0) was prepared as described 
above for G0F except starting with material from expression supplemented with 250 µM 
2–deoxy–2–fluoro–L–fucose. Digalactosylated IgG1 Fc (G2F) was prepared by 
incubating 5 mg of IgG1 Fc at 16 mg/mL, 20 mM MOPS, 100 mM sodium chloride, 20 
mM manganese chloride, 10 mM UDP–galactose, 2 μL of 100 mU/mL β–1,4 
galactosyltransferase (GalT), pH 7.2 at 37 °C for 24 h. Equal amounts of GalT and 
UDP–galactose were added after 24 h and the incubation was repeated. Following the 
glycan modification reactions, all samples were exchanged into a buffer containing 20 
mM MOPS and 100 mM sodium chloride, pH 7.2. Glycan remodeling was verified using 
MALDI–TOF MS as described previously 46 as well as spectra showing conversion of 
the material utilized herein 23. 
Preparation of endoglycosidase F1–treated CD16a (performed by DJF) 
Endoglycosidase F1 was expressed and purified as described 22 then coupled to 
agarose beads using the Amino–Link Plus Immobilization kit (ThermoSci). 
Endoglycosidase F1–agarose beads were stored at 4°C in 20 mM MOPS, 100 mM 
sodium chloride, pH 7.2. Beads were added to a solution containing 1.4 mg/mL CD16a 
in 100 mM potassium phosphate, pH 6.0 and incubated with end–over–end mixing at 4 
°C for 18 h. To isolate the remodeled CD16a, the solution was pipetted onto a MicroBio 
Spin column (BioRad) and gentle pressure applied to push the CD16a containing 
solution through leaving the beads behind, which were subsequently washed in buffer 
containing 20 mM MOPS, 100 mM sodium chloride, pH 7.2 and stored at 4°C.  
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Preparation of IgG1 Fc with truncated N–glycans (performed by DJF) 
Human IgG1 Fc glycovariants derived from HEK293F (+fuc) and HEK293S (afuc) 
were remodeled by endoglycosidases S 47 and F1 48 respectively, which cleave after the 
first sugar residue of the Asn297 chain. Each glycovariant of IgG1 Fc was exchanged 
into 100 mM potassium phosphate, pH 6.0 using a 10 kDa cutoff Amicon 
Ultracentrifugation filter. Both reactions were carried out at an IgG1 Fc concentration of 
115 µM with enzyme added at a 1/50 molar ratio at RT and incubated for 18 h.  
Binding analysis using surface plasmon resonance (performed by DJF and GPS)  
IgG1 Fc was immobilized on a CM5 chip surface (GE Life Sciences) by 
performing standard amine coupling procedures on a Biacore T100 instrument. The 
carboxymethyl dextran surface was activated by 1:1 mixture of 0.4 M 1–ethyl–3(3–
dimethylaminopropyl)carbodiimide hydrochloride and 0.1 M N–hydroxy–succinimide for 
7 min at a flow rate of 5 µl/min. IgG Fc was applied to the chip at 1 µg/mL in 10 mM 
sodium acetate, pH 5.0 buffer and at a flow rate of 5 µl/min. Residual functional sites 
were deactivated by washing with 1 M ethanolamine, pH 8.5 for 7 min. Final 
immobilization response units were between 400–700. Flow line 1 was used as a blank 
with no IgG1 Fc immobilized on all sensor chips. All SPR measurements were 
performed at 25°C. The binding analyses were performed with binding buffer containing 
20 mM MOPS, 100 mM sodium chloride, 1 µM bovine serum albumin and 0.05% P20 
surfactant (GE Life Sciences), pH 7.2. The CM5 chip surface was regenerated by a 100 
mM glycine, pH 3.0 wash for 30 s to remove bound receptor. A minimum of one 
replication for each condition was collected on different days. Representative results are 
shown. 
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Isothermal titration calorimetry (performed by DJF) 
CD16a was thawed and exchanged into a buffer containing 20 mM MOPS 100 
mM sodium chloride, pH 7.2 using a 5 mL Sephadex G25 column. IgG Fc variants were 
exchanged into a buffer containing 20 mM MOPS 100 mM sodium chloride, pH 7.2 prior 
to an experiment using an Amicon 10 kDa cutoff Ultra centrifugal filter (Millipore). 
Protein concentrations were determined using the calculated molar extinction 
coefficients (75,000 M–1cm–1 for Fc dimer, and 64,205 M–1cm–1 for CD16a–GFP fusion) 
for each protein on a NanoDrop 2000c spectrophotometer (ThermoScientific.) All 
binding experiments were performed on a GE MicroCal 200 instrument with the 
following settings: reference power = 1, stirring speed = 500 rpm, and 30 injections (1 x 
0.2 µL, 29 x 1 µL for all experiments). CD16a (16 – 26 µM) was loaded in the sample 
cell and IgG1 Fc was loaded into the syringe (117 – 250µM). Each set of experiments 
also contained a heat of dilution experiment, for these experiments the relevant IgG1 Fc 
variant (in the syringe) was titrated into a cell containing 20 mM MOPS, 100 mM sodium 
chloride, pH 7.2. All data analysis was conducted with the Origin software using a single 
site model (GE LifeSciences).  
Intact glycoprotein analysis by LC–ESI/MS (performed by DJF) 
Protein (10 µL, 0.1 mg/mL in double distilled water) was applied to a C4 column 
and eluted from an Agilent 1260 liquid chromatography system with variable relative 
concentrations of Buffer A (0.1 % formic acid in water) and Buffer B (0.1 % formic acid 
in acetonitrile) with a constant flow rate of 0.1 mL/min: 1 mL 95% A plus 5% B, then 0.5 
mL 100% B, and final 0.5 mL 95% A plus 5% B. ESI was conducted on a Q–Exactive 
Hybrid Quadrupole–Orbitrap Mass Spectrometer (Thermo Scientific) with positive 
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polarity at 35.0 eV, and a scan range of 700–4000 m/z. Data was displayed and 
processed using ProteoWizard 3.0.9220 (http://proteowizard.sourceforge.net) and 
mMass 49.  
Crystallization of the IgG Fc and CD16a(Man5) complex (performed by GPS and 
AMM) 
  For crystallization, the N–terminal His8–GFP tag of CD16a (N38Q/N74Q/N169Q) 
expressed in lec1–/– was removed by TEV protease digestion (1:50 TEV:GFP–CD16a 
ratio) in a buffer containing 50 mM Tris(hydroxymethyl)aminomethane, 100 mM sodium 
chloride, 0.5 mM Ethylenediaminetetraacetic acid (EDTA), pH 8.0, at RT overnight in 
the dark. CD16a was then purified by passing over a Ni–NTA column (QIAGEN). Flow 
through fractions were exchanged into a buffer containing 20 mM MOPS, 100 mM 
sodium chloride, pH 7.2 using a 10 kDa molecular weight cutoff Amicon Ultra centrifugal 
filters (Millipore). TEV–cleaved CD16a was mixed with IgG Fc at a molar ratio of 1:1.5 
(CD16a:Fc) and applied to a Superdex200 size exclusion column (GE Healthcare) pre–
equilibrated with 20 mM MOPS, 100 mM sodium chloride, pH 7.2. Factions containing 
the Fc:CD16a complex were identified by SDS–PAGE, pooled, and concentrated to 20 
mg/ml. Initial crystallization screens were performed by hanging drop vapor diffusion 
method at 18°C. Small, dispersed, rod–like crystals were obtained with various buffers 
and salts in two weeks. The initial crystal hits obtained in 16% PEG 20K, 0.1 M Bis–
Tris–Propane, pH 7.5. Pyramid shaped crystals were obtained in one week after 
microseeding in crystallization solution containing 1:1 mixture of protein to reservoir 
solution of 16% PEG 20K, 0.1M Bis–Tris–Propane pH 7.5 and 0.1M potassium 
thiocyanate. 
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X–ray diffraction and data processing (performed by AMM) 
Pyramid shaped crystals were cryoprotected with a quick soak in 20% Ethylene 
glycol, 20% PEG 20K, 0.1M Bis–Tris–Propane, pH 7.5, and 0.1M potassium 
thiocyanate. Diffraction data were collected at Argonne National Labs on beamline 23–
ID–B using a MAR300 detector. Phases were determined by molecular replacement 
using Phenix 50 and a Fc:FcγRIIIa model (PDB: 3SGK 27). Final refinement was 
performed with NCS and TLS restraints using Refmac5 in the CCP4 package 51 and 
data deposited as PDB as entry 5VU0.  
Molecular dynamics simulations of CD16a (performed by DJF) 
All simulations were performed with a desktop computer running the GPU 
version of Amber14 (pmemd.cuda 52) and the Amber force fields ff12SB and 
GLYCAM_06j–1 53 as previously described 35. CD16a (N38Q/N74Q/N169Q) was 
simulated for 1 µs, in complex with IgG1 Fc G0 or G0F for 250 ns (12,500 frames). A 
pentapeptide fragment containing a N–glycan at position 3 was simulated for 1µs. 
CUDA acceleration of Amber14 (pmemd.cuda) permitted rapid simulation with an in 
house desktop system equipped with two Nvidia GTX960 cards in about 30 days per 
simulation. Simulations were performed in duplicate. Conformational analysis was 
performed using VMD and custom scripts to extract appropriate information from each 
frame.  
Accelerated MD (aMD) simulations were performed using Amber16 
(pmemd.cuda) and the Amber force fields ff14SB and GLYCAM-06EPb with TIP5 
waters and equilibrated in the same manner as the non-accelerated structures. Boost 
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parameters for the dihedral and potential energies were calculated as described 37. The 
average dihedral and potential energies were calculated from the respective all-atom 
simulations described above. For the IgG1 G0–CD16a complex the inputs used are as 
follows: average dihedral = 7,965 kcal/mol, average potential energy = -417410 
kcal/mol, total atoms = 221028, and residues = 638. The resultant boosts for the IgG1 
Fc G0–CD16a complex are then: E(dihedral) = 10198 kcal/mol, α (dihedral) = 446.6 
kcal/mol, E (total) = -373205 kcal/mol, and α (total) = 44205 kcal/mol. For the IgG1 G0F-
CD16a complex the inputs used are as follows: average dihedral = 8000 kcal/mol, 
average potential energy = -418383 kcal/mol, total atoms = 222123, and residues = 
640. The resultant boosts for the IgG1 Fc G0F–CD16a complex are then: E(dihedral) = 
10240 kcal/mol, α (dihedral) = 448 kcal/mol, E (total) = -373958 kcal/mol, and α (total) = 
44424 kcal/mol. 
NMR spectroscopy (performed by DJF and GPS) 
NMR spectra were obtained using a 700–MHz Bruker Avance II spectrometer or 
an 800–MHz Avance III spectrometer; both spectrometers were equipped with 5 mm 
cryogenically cooled probes and resultant spectra initially analyzed using Topspin 3. 
Experiments on IgG1 Fc were collected at 50 °C in a buffer containing 20 mM MOPS, 
100 mM sodium chloride and 10% D20, pH 7.4. 15N-[Tyr,Phe] CD16A was expressed in 
HEK293S cells as described previously 39. Briefly, [15N]-Tyr and [15N]-Phe were added 
to the culture media at 100 mg/L each during protein expression. NMR data for CD16a 
were collected at 25°C. CD16a samples were exchanged into a buffer containing 20 
mM sodium phosphate, pH 7.4, 100 mM sodium chloride, 0.05 mM 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) and 10% D2O with a concentration between 100-200 
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μM in 200 μL. Spectra were processed using NMRpipe 54 and visualized using 
NMRViewJ (One Moon Scientific). All spectra were referenced to 4,4–dimethyl–4–
silapentane–1–sulfonic acid (0.07 ppm). 
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CHAPTER 5. DIRECT CHARACTERIZATION OF THE MAIZE STARCH SYNTHASE 
IIA PRODUCT SHOWS MALTODEXTRIN ELONGATION OCCURS AT THE NON-
REDUCING END  
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Abstract  
A comprehensive description of starch biosynthesis and granule assembly 
remains undefined despite the central nature of starch as an energy storage molecule in 
plants and as a fundamental calorie source for many animals. Multiple theories 
regarding the starch synthase (SS)-catalyzed assembly of (α1-4)-linked D-glucose 
molecules into maltodextrins generally agree that elongation occurs at the non-reducing 
terminus based on the degradation of radiolabeled maltodextrins though recent reports 
challenge this hypothesis. Surprisingly, a direct analysis of the SS catalytic product has 
not been reported to our knowledge. We expressed and characterized recombinant Zea 
mays SSIIa and prepared pure ADP-[13CU]-glucose in a one-pot enzymatic synthesis to 
address the polarity of maltodextrin chain elongation. We synthesized maltoheptaose 
(DP7) using ADP-[13CU]-glucose, maltohexaose (DP6) and SSIIa. Product analysis by 
ESI-MS revealed the [13CU]-glucose unit was added to the non-reducing end of the 
growing chain, and SSIIa demonstrated a >7,850-fold preference for addition to the non-
reducing end versus the reducing end. Independent analysis of [13CU]-glucose added to 
maltohexaose by SSIIa using solution NMR spectroscopy confirmed the polarity of 
maltodextrin chain elongation. 
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Introduction 
The development of starch biosynthesis by the Archaeplastida progenitor 
provided an efficient and dense energy storage molecule that dramatically altered 
terrestrial life on planet earth (1). More recently, starch formed an integral component of 
human evolution and societal development (2). By virtue of its importance, starch 
biosynthesis and molecular structure is studied intensely because fundamental 
questions remain, in particular, how glucose chains are synthesized and how different 
enzymes contribute to creating repeating three-dimensional structure in the starch 
granule. 
Starch is composed of two types of polymers with repeating D-glucose units 
termed amylose and amylopectin, which constitutes ~25% and ~75% of the granule 
mass, respectively. Amylose contains approximately 1,000-3,000 glucose units joined in 
almost exclusively α1-4 glycosidic bonds, divided into about 3-10 “linear” chains 
attached to each other by α1-6 “branch” linkages (3). Amylopectin is >95% α1-4 linked 
with ~5% branching α1-6 linkages, and contains approximately 5,000-10,000 glucose 
units (3,4). Amylopectin and amylose are initially synthesized as (α1-4)-linked 
maltodextrins from ADP-α-D-glucose donor molecules by starch synthase enzymes, of 
which five classes are conserved in land plants, as shown in Figure 1 (5). Amylose is 
predominately synthesized by granule-bound starch synthase (GBSS) (6). SSI, SSIIa 
and SSIII are all involved in producing the linear chains of amylopectin, and SSIV along 
with SSIII appear to be involved in the initiation of granule formation (7,8). Short to 
medium chain maltodextrins are modified by other enzymes including starch branching 
enzyme, phosphorylase, and starch debranching enzyme to give rise to amylopectin. 
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Amylose and amylopectin synthesis is tightly controlled to properly assemble the 
higher order structure in the starch granule that is required to expel water, though 
surprisingly little is known about this process. According to widely accepted models, the 
nascent structure is radially arranged around the initiation site with the non-reducing 
ends facing away from the initiation site. This is thought to be favorable because the 
starch granules are degraded from the non-reducing termini meaning more surface area 
for efficient metabolism (1). Amylopectin forms dehydrated regions of semi-crystalline 
and amorphous lamellae with a periodicity of 9 nm (1). The overall shape and size of 
starch granules can vary between species, and is heavily influenced by environment, 
however the periodicity of the lamellae remains constant (5). 
 
 
Figure 1. A simplified model depicting starch granule synthesis. Glucose is converted to 
ADP-glucose by hexokinase (HK), phosphoglucomutase (PGM) and ADP-glucose 
pyrophosphorylase (ADPGP). Starch synthase (SS) isoforms utilize ADP-glucose to 
synthesize growing maltodextrin chains that are branched by starch branching enzyme 
(BE) and starch debranching enzyme (DBE). On the lower left is the “cluster model” of 
amylopectin organization that forms the structural component of a starch granule, 
cutaway in the image on the lower right to show layers of amylopectin.  
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 The chemical structure of amylose and amylopectin implies that the fundamental 
process in the construction of starch granules is elongation of α1-4 linked glucan chains 
by SS. The polarity of D-glucose addition to a growing maltodextrin chain remains a 
primary question in starch biosynthesis and would affect enzymatic mechanisms put 
forward by several groups (9-11). Leloir and colleagues first addressed this question 
and demonstrated that the [14C]-glucose moiety from UDP-[14C]-glucose or ADP-[14C]-
glucose was incorporated into both amylose and amylopectin within starch granules 
(12-14). Digestion of these granules with the exo-acting enzyme α-amylase released 
[14C]-maltobiose, indicating D-glucose is added to the non-reducing end of the growing 
maltodextrin polymers. Further evidence for a non-reducing end addition mechanism 
was found upon analysis of reaction products with chemical degradation methods that 
distinguish polarity. In this case, [14C]-glucose addition (in the form of UDP-[14C]-
glucose) to unlabeled maltotriose or maltotetraose using SS from starch granules 
occurred at the non-reducing pole (13). Robyt and coworkers recently challenged these 
findings and concluded that maltodextrin elongation occurs at the reducing end using 
similar pulse and chase experiments that also lacked direct evaluation of the products 
(9,15,16). Both of these laboratories used enzyme mixtures from natural sources and 
degradation methods that are subject to errors. 
 The advent of recombinant protein expression techniques provided a new source 
of pure enzyme isoforms (8,17-23). These studies detailed the effect of amino acid 
substitutions to SS enzymes as well as kinetic characterization of substrate acceptors, 
however, none of these studies directly characterized the acceptor product to address 
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the polarity of maltodextrin growth, and many show only single additions from the SS 
enzymes.  
 In this study we expressed and purified recombinant Zea mays SSIIa to address 
the polarity of D-glucose addition using sensitive, high-resolution MS and NMR 
techniques. We chose maltohexaose (DP6) as the primary substrate because SSIIa 
was shown to elongate DP6 chains in a distributive manner (8).  
Results 
Expression, purification and analysis of ZmSSIIa (performed by DJF and MEL) 
 
SSIIa from Zea mays (ZmSSIIa) expressed in Escherichia coli as a single 
polypeptide with a molecular weight 77.3 kDa as shown in Figure 2. The majority of the 
protein expressed in an insoluble form, though soluble S-tagged ZmSSIIa constituted 
the predominant protein (>80%) following purification with S-protein agarose beads. 
This recombinant protein expression system eliminates potential contamination from 
other competing SS isoforms or other maltodextrin-modifying enzymes that would be 
present using starch granules as an enzyme source. ZmSSIIa bound to S-agarose 
beads was used as the enzyme source for all subsequent analyses. Previous analyses 
using this expression system demonstrated that the kinetic parameters of the enzyme 
were essentially identical whether it was bound to beads or free in solution after release 
from the matrix (23). 
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Figure 2. Expression and purification of ZmSSIIa analyzed by SDS-PAGE and 
coomassie staining. S-tagged enzyme was expressed and purified from Escherichia coli 
and captured using an S-protein agarose resin. ZmSSIIa-bound agarose beads were 
boiled in SDS-containing loading buffer before loading to analyze purity. (Performed by 
MEL and DJF) 
 
 ZmSSIIa utilized ADP-glucose in the presence of maltodextrin or glycogen. The 
rate of ADP generation was higher with 10 mg/mL glycogen as an acceptor substrate 
when compared to the rate with 10 mM maltohexaose (DP6) as shown in Figure 3A. It is 
difficult to directly compare the initial velocities of these two reactions due to the 
undefined concentration of acceptor sites in the reaction containing glycogen. We 
observed background intensity in reactions that contained ADP-glucose (Fig 3B). This 
background increased noise in the experiments but proved smaller than the rates 
observed with enzyme, acceptor and ADP-glucose present.  
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Figure 3. ZmSSIIa activity quantified by ADP release using the ADP-Glo reagent 
(Promega). (A) ZmSSIIa activity using maltohexaose (DP6) or glycogen as acceptor 
molecules. (B) The ADP-glucose preparation contributed to observed signal in the 
assay that was less than the ADP generated in reactions containing the combination of 
ADP-glucose, an acceptor substrate and SSIIa. (Performed by MEL AND DJF)   
 
 Analysis of the maltodextrin products revealed multiple additions to 
maltohexaose (DP6) during the ZmSSIIa-catalyzed reaction. TLC analysis of the 
substrates and products showed the near complete disappearance of ADP-glucose, the 
formation of primarily maltoheptaose (DP7) in the early stages of the reaction and a 
distribution of larger forms (DP8-14) in the later stages from a reaction containing 
ZmSSIIa (Fig 4). A similar reaction lacking the DP6 acceptor substrate showed no 
product formation and consistent ADP-glucose levels. MALDI-TOF MS analysis of the 
maltodextrin reaction products showed the same result (data not shown). The 
sequential addition of glucose residues to maltohexaose is consistent with reports that 
SSIIa acts in a distributive manner (6,8). 
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Figure 4. Analysis of ZmSSIIa products in a reaction containing maltohexaose (DP6) 
and ADP-glucose shows incorporation of multiple glucose units. (A) TLC analysis 
showing the result of two reactions. (B) Quantification of band intensity from (B). 
(Performed by DJF and MEL) 
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 These data indicate the ZmSSIIa preparation was active in solution and 
catalyzed multiple additions, but do not provide information regarding the polarity of 
maltodextrin chain growth. Once maltodextrin is extended it is impossible to distinguish 
newly added glucose residues from those present in the starting material. We 
synthesized ADP-[13CU]-glucose for use as a donor substrate in a ZmSSIIa-catalyzed 
reaction to eliminate isotopic symmetry of the maltodextrin product. 
 
One-pot synthesis of ADP-[13CU]-glucose (Performed by MEL) 
We pursued a one-pot, enzyme-catalyzed reaction scheme to prepare ADP-
[13CU]-glucose and avoid losses from purifying pathway intermediates (Figure 5A). 
Hexokinase, phosphoglucomutase, a thermostable ADP-glucose pyrophosphorylase 
(GlgC2) and an inorganic pyrophosphorylase were active in a HEPES, pH 7.5 buffer 
and converted >99% of the starting [13CU]-glucose to ADP-[13CU]-glucose. A 1H NMR 
spectrum of ADP-[13CU]-glucose purified by anion exchange chromatography revealed 
no identifiable peaks corresponding contaminating species other than a pH buffer and a 
chemical shift standard (DSS; Fig 5B). Seven strong peaks observed in a 2d 
heteronuclear (1H-13C) single quantum coherence (HSQC) spectrum were consistent 
with a highly purified sample free of contaminating nucleotide, free glucose or other 13C-
enriched molecule (Fig 5 C). ZmSSIIa utilized the isotopically-labeled donor substrate 
as efficiently as unlabeled ADP-glucose (data not shown). 
 
ESI-MS/MS analysis of 13C-labeled maltodextrin (Performed by DJF and MEL) 
It is possible that ZmSSIIa adds glucose to the reducing end of maltodextrin, the 
non-reducing end, or a combination of both. We analyzed the reaction products directly 
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to determine the polarity of ZmSSIIa-catalyzed maltodextrin chain elongation. The 
analytic scheme diagramed in Figure 6A utilizes unlabeled maltohexaose (DP6) as an 
acceptor substrate and ADP-[13CU]-glucose as the donor. Reaction times were limited 
by removing enzyme-linked agarose beads to terminate catalysis. Next, reductive 
amination completely modified the reducing end of the product and unreacted 
maltodextrin substrate with N-(naphthyl)-ethylenediamine and provided a handle for 
reversed-phase chromatography prior to ESI-MS. The MS spectrum indicated DP7 
constituted a majority of the product with a small amount converted to DP8 and 
differences of <0.01 Da separated the expected and observed masses for all species 
(Fig 6B). We observed multiple singly-charged forms corresponding to +H+, +Na+ and 
+K+ adducts of each reaction product and unreacted substrate using the positive 
instrument mode. 
 
 
Figure 5. Synthesis and characterization ADP-[13CU]-glucose. (A) [13CU]-glucose was 
completely converted using a one-pot enzymatic synthesis. (B) 1d NMR 1H spectrum of 
purified ADP-[13CU]-glucose shows a high degree of purity. A chemical shift standard 
(DSS) was added to this sample for the NMR data collection. (C) 2d 1H-13C HSQC of 
ADP-[13CU]-glucose showing assigned peaks. (Performed by MEL and AWB) 
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Once ions corresponding to modified substrate and product molecules were 
identified in MS spectra (Fig 6B), the polarity of [13CU]-glucose addition was determined 
by fragmenting the parent ions in a second MS dimension. If the [13CU]-glucose 
molecule was added to the reducing end, the [13CU]-glucose would be directly attached 
to the N-(naphthyl)-ethylenediamine tag. However, if the [13CU]-glucose molecule was 
added to the non-reducing end, the N-(naphthyl)-ethylenediamine tag would be 
attached to an unlabeled [12C]-glucose unit. If both ends were modified, a mixture of 
species [12C]- and [13CU]-labeled species would be identified and could be directly 
compared to determine the reaction preference. The isolation of specific parent ions 
from the first MS dimension using the Orbitrap instrument prevents cross-contamination 
of different parent ion species and thus selective MS/MS spectra. 
Ion selection provided very high signal-to-noise measurements in the MS/MS 
spectra. The MS/MS spectrum of the DP6 substrate that corresponded to the parent 
ion, and a neutral losses of n*(~162.1) which indicates loss of n [12C]-glucose units 
where n=1,2,3,4,or 5 (Fig 6C). As expected for the unlabeled substrate, the reducing 
end N-(naphthyl)-ethylenediamine tag coupled to a [12C]-glucose was also found with a 
mass of 351.2 Da. MS/MS spectra of the labeled DP7 reaction product revealed a 
neutral loss of ~168.1 Da when compared to the parent ion, indicating loss of a [13CU]-
glucose unit from the non-reducing end (Fig 6D). Spectra revealed no evidence for the 
neutral loss of ~162.1 Da from the parent ion. Furthermore, the second dimension 
spectrum contained reducing end N-(naphthyl)-ethylenediamine tag coupled to a [12C]-
glucose (351.2 Da) and revealed no evidence of a N-(naphthyl)-ethylenediamine tag 
coupled to a [13C]-glucose (357.2 Da; Figure 7). Comparison of the signal intensity of 
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the peak at 351.2 Da to the noise level observed surrounding 357.2 Da revealed that 
ZmSSIIa prefers the non-reducing end of maltohexaose for >99.987% of glucose 
addition reactions. 
Similar degradation patterns of the DP8 reaction product in MS/MS spectra 
provided complementary data to that described for DP7, above (Fig 6E). In this instance 
neutral loss of one labeled glucose unit (~168.1 Da) or two labeled units (~336.2) from 
the parent ion indicated addition at the non-reducing end, and [13C]-glucose modified by 
the chemical tag and thus located at the reducing end was not detected. 
 
NMR analysis of 13C-labeled maltodextrin (Performed by MEL and AWB) 
Labeling maltodextrins with stable isotopes provides an opportunity to validate 
the ESI-MS/MS analysis of SSIIa recognition polarity with an orthogonal technique. 
[13CU]-Glucose addition to the non-reducing end of maltodextrin can be distinguished 
from reducing end modification using solution NMR spectroscopy (Fig 8). The anomeric 
1H1 and 13C1 nuclei (Fig 8A) display characteristic resonance frequencies depending 
upon the chemistry of the glycosidic linkage and stereochemistry of the hemiacetal 
moiety. A glucose residue at the reducing end of a maltodextrin will have an anomeric 
configuration that mutarotates between α and β forms with 1H1 resonance frequencies 
at 5.19 and 4.62 ppm, respectively (Fig 8B). A glucose residue at the non-reducing end 
or within the interior of the polymer will be locked in the α configuration with a 1H1 
frequency of 5.37 ppm. Carbon [13C] chemical shifts are likewise distinct. 
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Figure 6. Multi-dimensional MS analysis of maltoheptaose (DP7) and maltooctaose 
(DP8) synthesized from unlabeled maltohexaose (DP6) using ZmSSIIa and ADP-[13CU]-
glucose. (A) The analytical scheme applied herein. Following conversion, the reducing 
end is modified through reductive amination. (B) ESI-MS spectrum of the reaction 
products showing conversion to DP7 and DP8; monoisotopic masses are provided. MS-
MS spectra of the parent ions for DP6 (C), DP7 (D) and DP8 (E). Ions are identified at 
the bottom of the figure with connections through vertical dashed grey lines and clearly 
indicate only modification of the DP6 non-reducing terminus. (Performed by DJF, MEL, 
and AWB) 
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Figure 7. ZmSSIIa catalyzes growth at the non-reducing end of maltohexaose with at 
least a 7850-fold preference over addition to the reducing end. These data represent 
expansions of Figure 6C and the molecule symbols match those in Figure 6. 
(Performed by DJF, MEL, and AWB) 
 
 2d HSQC NMR spectra of a reaction similar to that described for the ESI-MS/MS 
analysis between maltohexaose, ADP-[13CU]-glucose and ZmSSIIa revealed 1H-13C 
correlations (Fig 8C). Peaks for all three expected anomeric correlations in a mixture of 
maltohexaose (DP6) and maltoheptaose (DP7) were identified (non-reducing end α, 
reducing end α, reducing end β). 1H-13C correlations for the free anomeric carbons are 
due to the ~1% natural [13C] abundance, rather than to labeling with incorporated [13CU]-
glucose, because they appear in spectra of unreacted maltohexaose substrate (data not 
shown). The peak for the bound anomeric [13C] carbons, which includes the non-
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reducing end, has much greater intensity than the free anomeric carbon peak. The 
presence of a strong peak in the HSQC spectrum corresponding to the alpha form of 
the non-reducing end indicated the reaction specifically modified the maltohexaose non-
reducing end with [13CU]-glucose. 
 The effect of natural [13C] abundance in NMR spectra of labeled maltodextrins 
may be reduced by utilizing 13C-13C pairs to probe the added [13CU]-glucose unit 
specifically with an HCCH-TOCSY pulse sequence commonly applied to assign amino 
acids sidechain resonances in uniformly 13C-labeled proteins (24). This experiment 
passes magnetization between adjacent 13C-13C pairs (1H1-13C1-13C2-1H2, for 
example), which by natural abundance represent only 1 in 10,000 carbon atoms, but 
98% of the carbons in the [13CU, 99%]-glucose. Any correlations that meet these criteria 
are found as off-diagonal peaks in a plot showing 1H frequency on the x and y axes. 
Peaks located along the diagonal (that have the same 1H frequency in both the x and y 
dimensions) indicate no transfer occurred and are not informative (Fig 8D-F). 
A 2d 1H(CC)1H-TOCSY experiment on the material prepared using the reaction 
described above showed correlations between the 1H1 of the non-reducing end glucose 
(observed on the x axis) and the 1H2 nucleus (located on the vertical dashed grey line 
and surrounded by a dashed red box in Fig 8D), but no similar cross peaks for either the 
α or β 1H1 glucose residue on the reducing end (marked by grey “H2” labels in Fig 8D). 
An artifact peak was observed (marked “a” in Fig 8D-F), but was identified as a minor 
contaminant from the ADP-[13CU]-glucose substrate (Fig 8F) not present in the 
maltohexaose substrate (Fig 8E).  
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We observed a small amount of H2 signal from an HCCH-TOCSY spectrum of 
the unlabeled maltohexaose substrate due to natural abundance 13C upon lowering the 
contour level to nearly that of noise (Fig 8E). Though the signal from [13CU]-glucose was 
much stronger, we explored the result of a longer magnetization transfer pathway to 
suppress background signals an additional 100-fold (or 1 in 1,000,000). This pathway 
involved three 13C transfers and can be seen in the “H3” peaks in Fig 8D (1H1-13C1-
13C2-13C3-1H3). H3 signals from a reducing end glucose residue were not observed. 
These HCCH-TOCSY spectra agree completely with the HSQC spectra and ESI-
MS/MS analysis and unambiguously identify the non-reducing end of maltohexaose as 
the primary acceptor site for ZmSSIIa-catalyzed maltodextrin elongation. 
 
Discussion 
This study directly characterized the chemical structure of ZmSSIIa reaction 
products. MS analyses that directly distinguished the position of the newly added 
glucosyl moiety showed a striking preference for the non-reducing end within a 
sensitivity limit that cannot exclude one reducing end addition for more than 7,850 
glucose units incorporated. NMR spectra proved less sensitive than the ESI-MS spectra 
and could not independently support the >7850:1 addition ratio, however, observation of 
1H correlation signals requiring two or three adjacent 13C atoms qualitatively 
demonstrated that the great majority of additions are at the non-reducing end. Taken 
together these two analytical techniques provide definitive evidence that ZmSSIIa 
catalysis is specific for the non-reducing end of a maltodextrin acceptor substrate. The 
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techniques described here can be used to directly assess this prediction for any other 
plant SS, or glycosyl transferases from other species. 
ZmSSIIa activity was undetectable when maltohexaose was omitted from the 
reaction. This was evident from the lack of maltodextrin products detected either by TLC 
or MALDI-TOF, and from the consistent ADP-glucose levels (Figure 4A, right side). 
Thus, in this reconstituted system the activity of SSIIa is strictly dependent on the 
presence of a maltodextrin acceptor substrate.  
These results support the original conclusion of Leloir and coworkers that SS 
present within starch granules adds primarily to the non-reducing end (12-14). It is 
unclear why Robyt and Leloir arrived at different conclusions despite the use of similar 
techniques and comparable material sources, though both relied upon indirect analysis 
techniques that characterized hydrolyzed glucose units following reduction or oxidation 
of the maltodextrin chain (9,15,16,25). The technique employed by Robyt and 
coworkers would have been sensitive to unanticipated starch degradation that occurred 
prior to chemical modification and maltodextrin hydrolysis. Such degradation could have 
occurred enzymatically because none of the enzyme preparations used in the previous 
studies were biochemically pure, or they could have resulted from unforeseen chemical 
reactions. The independent characterization techniques used here that employed a 
purified recombinant enzyme and a defined maltohexaose molecule as a potential 
acceptor substrate, plus the direct and targeted characterization of the reaction product, 
avoid any such potential artifacts. 
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Figure 8. NMR analysis of maltodextrins synthesized using ZmSSIIa and ADP-[13CU]-
glucose. (A) Model of maltohexaose (DP6) showing nomenclature. The anomeric 1H 
regions of (B) 1d NMR 1H and (C) 2d 1H-13C HSQC spectra collected on a reaction of 
unlabeled DP6, ZmSSIIa and ADP-[13CU]-glucose creating a small amount of DP7 
(comparable to the conversion in Fig 6B). A small amount of natural abundance signal 
is observed, particularly for the  and  forms at the reducing end. HCCH-TOCSY 
spectra of the reaction (D) shows clear 13C-13C transfer occurred only in a [13CU]-
glucose unit added to the non-reducing end of the maltodextrin as highlighted with a 
dashed red box. Similar experiments collected on the acceptor substrate (E) and the 
donor substrate (F) do not show these features. (Performed by MEL and AWB) 
 
Another explanation for differing conclusions of maltodextrin chain elongation 
polarity is that different SS enzymes employ distinct reaction mechanisms. It is formally 
possible ZmSSIIa utilizes a different mechanism than GBSS or the mixture of SS 
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enzymes studied by the Leloir and Robyt laboratories (12,26). This explanation appears 
to be unlikely due to the high degree of primary, secondary and tertiary structural 
conservation across SS enzymes. SSI-IV, GBSS and bacterial glycogen synthases are 
members of the orthologous GT5 family of glycosyl transferases and though structures 
of all GT5 members are not available, analysis of reported structures indicates a high 
degree of structural similarity including rice GBSS (27), barley SSI (28), and glycogen 
synthase from E. coli (29,30) or Agrobacterium tumefaciens (31). A structure of the E. 
coli glycogen synthase bound to maltotriose (DP3) shows the maltotriose non-reducing 
C4-OH proximal to the beta phosphate group of ADP, where an incoming donor 
glucosyl moiety would be located (29,30). These observations suggest that GT5 family 
members, including SSs and glycogen synthases, employ similar mechanisms that 
extend maltodextrins by glucosyl addition to the non-reducing end. 
Materials and Methods 
All materials were purchased from Sigma Aldrich unless otherwise noted. 
 
ADP-glucose pyrophosphorylase purification (performed by MEL) 
  A pHM1 expression plasmid encoding hexahistidine-tagged wild type glgC2 from 
Thermotoga maritima was provided by Dr. Christopher Meyer (Cal State, Fullerton) 
(32,33). Escherichia coli BL21* cells containing the GlgC2 expression plasmid were 
grown in 1 L Luria-Bertani medium supplemented with 100 µg/mL ampicillin to an OD600 
of 0.5 at 37 °C in a rotary shaker. Protein expression was induced at this point with 1.5 
g L-arabinose and incubated with shaking overnight at 18 °C. The cells were 
resuspended in a lysis buffer containing 50 mM sodium phosphate, 300 mM sodium 
chloride, and 10 mM imidazole, pH 8.0 and lysed by multiple passages through an 
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Emulsiflex C5 homoginizer (Avestin) operating at 15,000 psi. The lysate was clarified by 
centrifugation at 16,000 x g for 1 h. The supernatant was applied to a 5 mL Ni-NTA 
column (Qiagen) was washed with 5 x 5 mL lysis buffer, 5 x 5 mL wash buffer (50 mM 
sodium phosphate, 300 mM sodium chloride, 5 mM dithiothreitol, pH 8.0) with 20 mM 
imidazole, 3 x 5 mL wash buffer with 100 mM imidazole, 3 x 5 mL wash buffer with 250 
mM imidazole, and 1 x 5 mL wash buffer with 500 mM imidazole. Fractions containing 
GlgcC2 protein were identified using SDS-PAGE, pooled, exchanged into lysis buffer 
using a centrifugal filter unit (Amicon, 10 kDa molecular weight cut off), diluted to a final 
concentration of 10% glycerol and stored at -80 °C. Protein concentration was 
estimated using a molar extinction coefficient of 57550 M-1 cm-1. 
 
ADP-[13CU]-glucose synthesis (performed by MEL)  
A one-pot reaction based on the conditions presented (34) and containing 200 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 20 mM magnesium chloride, 10 
mM [13CU]-glucose, 20 mM adenosine triphosphate, 0.0016 U/μL hexokinase (H4502, 
Sigma), 0.0076 U/μL phosphoglucomutase (P3397, Sigma), 0.0008 U/μL inorganic 
pyrophosphotase (l1643, Sigma), 0.14 mg/mL ADP-glucose pyrophosphorylase 
(GlgC2), pH 7.5 was incubated for 1 d at 25 °C. The reaction was monitored using a 
Bruker 700 MHz solution NMR system equipped with a 5 mm cryogenically-cooled 
probe. The reaction was filtered through a sterile 0.22 μm filter. ADP-[13CU]-glucose was 
purified from contaminating reaction components with a buffer containing 5% 1M 
sodium hydroxide and eluted with a 0-95% gradient of 1M ammonium acetate from a 
Carbo PAC PA-100 on a Dionex HPLC system (Thermo Scientific). Fractions containing 
ADP-[13CU]-glucose were pooled and lyophilized. The resulting powder was 
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resuspended in D2O and quantified using 1H NMR by comparison to an internal 4,4-
dimethyl-4-silapentane-1-sulfonic acid standard.  
 
SSIIa purification (performed by DJF and MEL)  
Zea mays SSIIa containing an N-terminal S-tag was expressed from a 
pET29:SSIIa plasmid and purified as previously described (23). The amount of protein 
attached to the S-protein agarose beads (EMD Millipore) was quantified by adding 10 
μL of 1:1 SSIIA bead:buffer slurry to 20 μL of 8 M urea followed by centrifugation. The 
A280 of the resulting supernatant was measured on a NanoDrop 2000C 
spectrophotometer (Thermo Scientific) and SSIIa concentration estimated using a molar 
extinction coefficient of 117730 M-1 cm-1.  
 
The SSIIa-catalyzed reaction (performed by DJF and MEL)  
Activity assays were performed after each purification. We noted that SSIIa 
activity reduced by ~50% after 1 week at 4 °C so each activity assay was performed on 
SSIIa that was not more than 1 week old. Reactions consisted of 20 mM glycine, 5 mM 
ethylenediaminetetraacetic acid, 0.5 mg/mL bovine serum albumin, 5 mM dithiothreitol, 
acceptor substrate (maltohexaose or shellfish glycogen), 2-4 mM ADP-glucose or ADP-
[13CU]-glucose, 5 μM SSIIa, pH 8.2 and were performed with shaking at 20-37 °C with 
constant gentle rotation to mix the beads and the solution. Aliquots were removed to 
monitor the reaction progress, then centrifuged for 1 min at 0.1 x g to separate the 
bead-bound SSIIa from the reaction supernatant.  
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SSIIa activity assayed using the ADP-GloTM kinase reagent (performed by DJF and 
MEL) 
Reaction supernatant (5 μL) was added to 85 µL of 40 mM 
tris(hydroxymethyl)aminomethane, 20 mM sodium chloride, and 0.1% (w/v) bovine 
serum albumin, pH 7.5 in a white 96 well microtiter plate. After all time points were 
collected, 10 μL of the kinase detection reagent (ADP-GloTM Kinase Assay, Promega) 
was added to each well and the plate was shaken for 5 min at 25 °C. Luminescence 
was measured using a Synergy 2 plate reader (Biotek) and compared to a standard 
solutions containing known amounts of ADP. 
 
Thin-layer chromatography (performed by DJF and MEL) 
Reaction supernatant (2 μL) was spotted on a silica gel 60 TLC plate (EMD 
Millipore). The plate was developed with a running solution of 85:20:50:60 
acetonitrile:ethyl acetate:isopropanol:water and dried. This process was repeated twice 
and following the third drying, the plate was thoroughly dried and dipped in a solution of 
95% methanol, 5% sulfuric acid, and 0.3% N-(1-naphthyl)-ethylenediamine-
dihydrochloride. The plate was allowed to air dry and then incubated in a 120 °C oven 
for 10 minutes or until the appearance of uniform color development (26). The 
maltodextrin standard was prepared by debranching shellfish glycogen with isoamylase 
(10U) (Megazyme) in pH 4.5 sodium acetate buffer at 22°C for 24 hours as previously 
described (35).  
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Analysis by matrix-assisted laser desorption ionization time of flight mass 
spectrometry (MALDI-TOF MS) (performed by MEL and AWB) 
Reactions were analyzed using a Voyager DE Pro Star MALDI-TOF instrument 
(Applied Biosystems). Reaction supernatant (0.5 μL) was mixed 0.5 μL of matrix 
solution (40mg/mL 2,5-dihydroxybenzoic acid in 80:20 acetonitrile:water) and applied to 
the MALDI plate. The crystals were shot in reflector mode with positive polarity and the 
following settings: laser intensity 2800, accelerating voltage 19000, grid 76%, guide wire 
0.2%, delay time 275 ns.  
 
Analysis by electrospray ionization-mass spectrometry (ESI-MS) (performed by 
AWB, DJF, and MEL) 
Reaction supernatant was further analyzed with an Agilent 1260 liquid 
chromatography system liquid chromatography system coupled with an ESI-MS (Q 
Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer; Thermo Scientific). First, 
samples were modified at the reducing end with reductive amination. Reaction 
supernatant (25 μL) was added to 20 μL of 0.2 M N-(naphthyl)-ethylenediamine 
dihydrochloride in 15% acetic acid, 5 μL of 5 M sodium cyanoborohydride and incubated 
at 37 °C for 15 h (5). Samples (10 μL) were injected at a flow rate of 0.03 mL/min onto a 
C18 reversed-phase column previously equilibrated with 95% solvent A (0.1% formic 
acid in water) and 5% solvent B (0.1% formic acid in acetonitrile) at 20°C. Samples 
were eluted using a linear gradient of 5-35% solvent B from 1 to 8 min followed by a 
linear gradient from 35-100% solvent B from 8 to 13 min. The ESI-MS instrument was 
set to positive polarity with 3600 kV spray voltage and a mass scan range of 100-1500 
m/z. MS/MS spectra were collected on select ions by higher-energy collisional 
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dissociation using 25 eV. Data were displayed and analyzed using Thermo XCalibur 
Qual Browser (version 3.0.63). 
 
Analysis of 13C-labeled dextrans by nuclear magnetic resonance spectroscopy 
(performed by MEL and AWB) 
Analysis was performed on a Bruker 18.8T MHz Avance III system equipped with 
a 5 mm cryogenically-cooled TXI probe. This system was equipped with TopSpin 3.2. 
Standard 1H detection, 1H-13C HSQC and HCCH-TOCSY experiments were performed. 
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APPENDIX A. SUPPLEMENTATION OF HEK 293 CELLS WITH 15N-LABELED 
AMMONIUM CHLORIDE 
 
Incorporation of stable isotopes into proteins via supplementation is a favored 
pathway to studying these molecules by NMR. In prokaryotes this can be accomplished 
by growing the plasmid-containing organism in a minimal media where the sources of 
carbon and nitrogen are strictly controlled. However, in mammalian systems the same 
minimal media scheme is not viable as mammalian cells cannot synthesize all amino 
acids, and have a much more diverse nutritional requirement. Glutamine is known to be 
essential to drive robust cell growth, and is usually supplemented into cell media in 
excess over all other amino acids. While other cells can directly use ammonia as their 
nitrogen source, mammalian cells require it is amino acid form. Industrial scale growth 
of mammalian cells for production of therapeutic proteins have tried supplementation 
with ammonia as a lower cost form of nitrogen, but show its toxic effect on cell growth at 
relatively low concentrations. 
For protein labeling this means that in order to label effectively all amino acids 
must be supplemented in whatever isotope for is desired. This requirement has made 
mammalian protein expression systems off-limits to most studying by NMR due to the 
cost of obtaining all 20 amino acids with various isotope labels. Post-translational 
modifications such as N-glycans however can be labeled effectively by supplementation 
with D-glucose.  
In order to increase the type of labels on N-glycans we proposed 
supplementation of the mammalian cell media with 15N-ammonium chloride. We 
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predicted that this would lead to a fraction of the glutamine pool bearing the 15N at the 
terminal amino group. Glutamine participates in the synthesis of many other amino 
acids, in addition to N-Acetyl-D-Glucosamine. Upon supplementation of the HEK cell 
media with 10mM 15N-ammonium chloride we found that we had indeed introduced 
labels into the protein and sugar (Figure 1 and 2). It appears that this form of 
supplementation incorporates into not only N-Acetyl-D-Glucosamine, but into the amino 
acids Asparagine, Aspartate, Glutamate, Glutamine, and Alanine according to our initial 
analysis. The average incorporation according to peptide data is around 40% of the 
amino acids listed above. It is unknown at this time, but suspected not all amino acids 
will be incorporated into at the same percentage.  
 
Figure A1. 1H-15N HSQC of CD16A supplemented with 10mM 15NH4Cl. 
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Figure A2. Endoglycosidase F1 released glycans from CD16A supplemented with 
10mM 15NH4Cl. 
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APPENDIX B. TWO DISULFIDE BOND ADDITIONS TO HUMAN IGG1 FC AND 
THEIR EFFECTS ON BINDING AND THERMOSTABILITY 
 
Increasing the stability of therapeutic proteins to improve their efficacy is well 
documented in the case of IgG1. IgG1 can bind the neonatal Fc receptor (FcyRN) thus 
increasing its lifetime in serum. An additional way to increase serum half-life is to 
engineer a more stable version of IgG1. Because IgG1 is made of repeated 
immunoglobulin folds finding which subunit is most likely to be the least stabilized and 
modifying it is key. In this example of working on the IgG1 Fc subunit, we feel the Cy2 
domain is the weaker subunit as the Cy3 participates in a strong homodimeric 
interaction. Over the course of MD simulations such as described in chapter 4, we have 
noticed that the C’E loop shows considerable motion on the timescales measured, and 
in the accelerated MD it completely dissociated from the other beta strands. This led us 
to consider a stabilization strategy to reinforce this loop. While work on mouse IgG2c 
showed us a potential pathway to stabilization through introduction of a salt bridge 
between residues we sought a stronger interaction, such as a disulfide bond. Using a 
software called Disulfide by Design, we probed the Cy2 domain for sites that would 
have the proper geometry and would be in the correct location to reinforce the C’E loop. 
We found such a site at V266 and Y300, which from our previous NMR work know that 
Y300 is a very sensitive residue to C’E loop conformation. In addition to this site, 
another was found that would bridge the FG and BC loops (D270 and K326), while our 
simulations did not emphasize this section in particular, we know from the work in 
chapter 3 that these loops impact each other and so covalently linking them could 
impart superior stability. With the help of Emily Knuth, we created three IgG1 Fc 
mutations: V266C/Y300C, D270C/K326C, and V266C/D270C/Y300C/K326C.  
126 
 
 
Crude analysis of the melting curves using a dye based thermal shift assay suggested 
that we had succeeded in shifting the melting analysis (Figure 1), however we are 
unsure as either the protein is stable past 100°C or there was some technical issue with 
the assay. We currently are looking into better methods for measuring denaturation of 
thermostable proteins. SPR was used to gauge the impact these mutations have in 
terms of binding the low affinity receptor CD16A. Initial runs of the three mutants 
showed that the mutation around the C’E loop completely destroys binding, whereas the 
mutation in the FG BC loop takes a ~2 fold reduction in affinity (Table 1.)  
 
 
Figure B1. Protein thermal shift assay of several IgG1 Fc cysteine mutations. 
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Table B1. Binding of various cysteine mutants of IgG1 Fc to CD16A lec wt. All material 
is HEK derived. 
IgG type Affinity (nM) 
wt Fc  338 
V266C/Y300C Fc n.d. 
V266C/Y300C Fc w/ EndoS truncated glycans n.d. 
D270C/K326C Fc 883 
D270C/K326C Fc w/ EndoS truncated glycans n.d. 
D270C/V266C/Y300C/K326C Fc n.d. 
D270C/V266C/Y300C/K326C Fc w/ EndoS treated glycans n.d. 
 
 
